<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Guide to the care of the hospitalized patient with ischemic stroke. 2nd edition.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Association of Neuroscience Nurses. Guide to the care of the hospitalized patient with ischemic stroke. 2nd ed. Glenview (IL): American Association of Neuroscience Nurses; 2008. 38 p.  [153 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The American Association of Neuroscience Nurses reaffirmed the currency of this guideline in December 2012.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="HCPCS: Dysphagia screening "/><FieldValue Value="ICD9CM: Cerebral artery occlusion, unspecified without mention of cerebral infarction  (434.90); Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); Diagnostic ultrasound of heart  (88.72); Dysphagia, unspecified  (787.20); Electroencephalogram  (89.14); Hemorrhage, unspecified  (459.0); Hypotension, unspecified  (458.9); Measurement of systemic arterial blood gases  (89.65); Neurologic examination  (89.13); Other late effects of cerebrovascular disease, dysphagia  (438.82); Unspecified intracranial hemorrhage  (432.9); Urinary tract infection, site not specified  (599.0)"/><FieldValue Value="MSH: Affective Symptoms ; Angioedema ; Angiography ; Aspirin ; Blood Cell Count ; Blood Chemical Analysis ; Blood Gas Analysis ; Brain Ischemia ; Deglutition Disorders ; Depression ; Diagnostic Techniques, Neurological ; Documentation ; Echocardiography ; Echocardiography, Transesophageal ; Electroencephalography ; Enalapril ; Fibrinolytic Agents ; Fluid Therapy ; Glasgow Coma Scale ; Hemorrhage ; Hydralazine ; Hypertension ; Hypotension ; International Normalized Ratio ; Intracranial Hemorrhages ; Labetalol ; Magnetic Resonance Imaging ; Medical History Taking ; Monitoring, Physiologic ; Myocardial Perfusion Imaging ; Neurologic Examination ; Nicardipine ; Nitroprusside ; Nutritional Physiological Phenomena ; Patient Education as Topic ; Platelet Aggregation Inhibitors ; Platelet Count ; Pneumonia ; Prothrombin Time ; Pulmonary Embolism ; Range of Motion, Articular ; Rehabilitation ; Skin Care ; Stroke ; Thrombolytic Therapy ; Tissue Plasminogen Activator ; Tomography Scanners, X-Ray Computed ; Tomography, X-Ray Computed ; Ultrasonography, Doppler, Duplex ; Urinary Tract Infections ; Venous Thrombosis ; Vital Signs "/><FieldValue Value="MTH: alteplase ; Analysis of arterial blood gases and pH ; Angioedema ; angiogram ; Aspirin ; Bladder care ; blood cell count ; Blood Chemical Analysis ; Blood Gas Analysis ; Blood glucose measurement ; Bowel care procedure ; Brain Ischemia ; Cerebrovascular accident ; Computed Tomography Scanning Systems ; Deep vein thrombosis of lower limb ; Deglutition Disorders ; Documentation ; Echocardiography ; Echocardiography, Transesophageal ; Electroencephalography ; Fibrinolytic Agents ; Fluid Management ; Fluid Therapy ; Glasgow coma scale ; Hemorrhage ; Hypertensive disease ; Hypotension ; International Normalized Ratio ; Ischemic stroke ; Magnetic Resonance Imaging ; Mental Depression ; Neurologic Examination ; Nutrition management ; Patient education (procedure) ; Plain chest X-ray ; Platelet Aggregation Inhibitors ; Platelet Count measurement ; Pneumonia ; Prothrombin time assay ; Pulmonary Embolism ; Range of Motion, Articular ; Rehabilitation assessment ; Rehabilitation therapy ; Skin Care ; Supportive care ; Urinary tract infection ; Venous Thrombosis ; Vital signs ; X-Ray Computed Tomography "/><FieldValue Value="PDQ: acetylsalicyclic acid ; angiography ; computed tomography ; dysphagia ; hypotension ; magnetic resonance imaging ; recombinant tissue plasminogen activator ; supportive care/therapy ; thrombolytic therapy "/><FieldValue Value="SNOMEDCT_US: Alteplase  (108997009); Alteplase  (27638005); Alteplase  (37411004); Alteplase  (387152000); Analysis of arterial blood gases and pH  (60170009); Analysis of arterial blood gases and pH  (91308007); Angioedema  (400075008); Angioedema  (41291007); Angiography  (77343006); Arteriography  (129118002); Aspirin  (387458008); Aspirin  (7947003); Barthel index  (273302005); Bladder care  (385961000); Blood cell count  (88308000); Blood chemistry  (166312007); Blood gas analysis  (167018008); Blood gas analysis  (278297009); Bowel care  (225361002); Cerebrovascular accident  (230690007); Computerized axial tomography  (77477000); CT angiography  (418272005); Deep venous thrombosis of lower extremity  (404223003); Difficulty swallowing  (288939007); Difficulty swallowing  (40739000); Duplex ultrasound  (312236008); Echocardiography  (40701008); Electroencephalogram  (54550000); Enalapril  (15222008); Enalapril  (372658000); Family education  (311403008); Family education  (460616007); Fluid balance regulation  (276026009); Glasgow coma scale  (386554004); Glucose measurement, blood  (33747003); Hemorrhage  (131148009); Hemorrhage  (50960005); Hydralazine  (22696000); Hydralazine  (387125005); Hypertension clinical management plan  (412779008); Hypertensive disorder  (38341003); Initial neurological assessment  (170692007); International normalized ratio  (165581004); International normalized ratio  (1951000175101); Intracranial hemorrhage  (1386000); Ischemic encephalopathy  (389100007); Ischemic stroke  (422504002); Labetalol  (372750000); Labetalol  (46547007); Low blood pressure  (45007003); Magnetic resonance imaging  (113091000); Magnetic resonance imaging  (312250003); Magnetic resonance imaging unit  (90003000); Neurological assessment  (225398001); Neurological assessment  (84728005); Nicardipine  (108526002); Nicardipine  (372502001); Nitroprusside  (372860000); Nitroprusside  (8163008); Nutrition management  (386372009); Patient education  (311401005); Physiologic monitoring system  (5159002); Plain chest X-ray  (399208008); Platelet count  (61928009); Pneumonia  (233604007); Prothrombin time  (396451008); Pulmonary embolism  (59282003); Range of joint movement  (364564000); Rehabilitation assessment  (423040001); Rehabilitation therapy  (52052004); Screening for dysphagia  (431765005); Skin care  (225360001); Support  (243114000); Thrombolytic  (303960004); Thrombolytic  (372742009); Thrombolytic therapy  (426347000); Transesophageal echocardiography  (105376000); Urinary tract infectious disease  (68566005); Venous thrombosis  (111293003); Vital signs  (46680005)"/><FieldValue Value="SPN: SYSTEM, NUCLEAR MAGNETIC RESONANCE IMAGING ; SYSTEM, X-RAY, TOMOGRAPHY, COMPUTED "/><FieldValue Value="UMD: Analyzers, Laboratory, Blood Gas  (18-617); Monitoring Systems, Physiologic  (12-636); Physiologic Monitor Modules, Electroencephalography  (20-783); Radiographic Systems  (18-429); Radiographic Systems, Digital, Chest  (18-431); Scanning Systems, Computed Tomography  (13-469); Scanning Systems, Magnetic Resonance Imaging  (16-260); Scanning Systems, Ultrasonic, Vascular  (15-957)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Ischemic stroke (cerebral infarction)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Counseling" /><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Critical Care" /><FieldValue Value="Emergency Medicine" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Neurological Surgery" /><FieldValue Value="Neurology" /><FieldValue Value="Nursing" /><FieldValue Value="Nutrition" /><FieldValue Value="Physical Medicine and Rehabilitation" /><FieldValue Value="Pulmonary Medicine" /><FieldValue Value="Radiology" /><FieldValue Value="Speech-Language Pathology" /><FieldValue Value="Surgery" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Emergency Medical Technicians/Paramedics" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Hospitals" /><FieldValue Value="Nurses" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;To translate the latest research into an easy-to-use reference&lt;/li&gt;&#xD;&#xA;&lt;li&gt;To provide guidelines for emergent evaluation of persons with suspected ischemic stroke&lt;/li&gt;&#xD;&#xA;&lt;li&gt;To provide nurses with a tool to help them deliver optimum-quality, patient-focused care for hospitalized individuals who have experienced an ischemic, cerebral infarct&lt;/li&gt;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Person presenting in field or emergency department with suspected or known ischemic stroke &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hospitalized patients with suspected or known ischemic stroke&lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Diagnosis/Evaluation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patient history and physical examination &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Neurological examination and assessment&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Use of National Institutes of Health Stroke Scale (NIHSS) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Barthel Index &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Modified Ranken scale &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Glasgow Coma scale&lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Laboratory evaluation&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Blood and platelet count, prothrombin time, international normalized ratio &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Blood glucose level &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Serum chemistries&lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Radiographic evaluation&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Computed tomography (CT) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;CT angiography and CT perfusion &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Arteriography &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Chest radiography &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Magnetic resonance imaging &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Carotid duplex scanning &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Basic and transesophageal echocardiography&lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Respiratory monitoring and arterial blood gas analysis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Electroencephalography &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitoring of vital signs&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management/Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Antithrombolytic therapy (recombinant tissue plasminogen activator [rt-PA], Activase) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypertension management (labetalol, nicardipine, sodium nitroprusside, hydralazine, enalapril) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitoring for hypotension and other complications of rt-PA therapy, including intracranial hemorrhage, angioedema, bleeding &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of intra-arterial thrombolysis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of mechanical thrombolysis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Oral antiplatelet therapy (aspirin) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitoring for and preventing medical complications of stroke &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;General supportive care&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Fluid management &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Nutrition management including evaluation and management of dysphagia &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Monitoring for pneumonia and urinary tract infection &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Bowel and bladder care &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Monitoring for and treatment of deep vein thrombosis and pulmonary embolism &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Performing range of motion exercises to prevent contractures and other orthopedic complications &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Skin care &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Recognition of depression and involuntary emotional expression disorder &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Rehabilitation consultation&lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient and family education &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Documentation&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Documentation in the emergency department &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Documentation during and after rt-PA administration &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Ongoing documentation&lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;Reliability and validity of assessment tools&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Prevention of reinjury of brain tissue&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Preservation of viable brain tissue&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Mortality&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Disability&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Rate of intracerebral hemorrhage&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Incidence of stroke complications&lt;/li&gt;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;2008 Original Guideline&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A review of the literature from January 1997 to February 2008 was conducted using the PubMed/Medline and CINAHL Information Systems Web sites with the search terms &lt;em&gt;stroke&lt;/em&gt;, &lt;em&gt;ischemic stroke&lt;/em&gt;, and &lt;em&gt;cerebrovascular disease&lt;/em&gt;. Monographs, textbooks, and review articles were also consulted. Studies not directly pertaining to the topic or not written in English were excluded from the review.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2012 Reaffirmation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Medline/PubMed, CINAHL, American Stroke Association guidelines, monographs, textbooks and other review articles were reviewed from 2000 to December 2012.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus" /><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Data Quality Classification&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class I&lt;/strong&gt;: Randomized controlled trial without significant limitations or meta-analysis&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class II&lt;/strong&gt;: Randomized controlled trial with important limitations (e.g., methodological flaws, inconsistent results); observational study (e.g., cohort, case control)&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class III&lt;/strong&gt;: Qualitative study, case study, or series&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IV&lt;/strong&gt;: Evidence from reports of expert committees and/or expert opinion of the guideline panel, standards of care, and clinical protocols that have been identified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This clinical practice guideline and recommendations for practice were based upon evaluation of the available evidence.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;2008 Original Guideline&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Not stated&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2012 Reaffirmation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Editorial Board does an annual review of guidelines.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level 1&lt;/strong&gt;: Recommendations are supported by class I evidence.&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level 2&lt;/strong&gt;: Recommendations are supported by class II evidence.&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level 3&lt;/strong&gt;: Recommendations are supported by class III and class IV evidence.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Published cost analyses were reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Blinded external peer review was performed using established criteria for evaluation.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The data quality classifications (&lt;strong&gt;I-V&lt;/strong&gt;) supporting the recommendations and levels of recommendations (&lt;strong&gt;1-3&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Methods, Procedures, Interventions, Education&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Assessment and Monitoring of a Patient with a Stroke&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Neurological assessment of a patient with a stroke is critical for preventing reinjury of brain tissue or preserving viable tissue. The clinical bedside examination, for a variety of reasons, remains the gold standard of neurological assessment (&lt;strong&gt;Level 3&lt;/strong&gt;; Jordan, 2004; Layton, Gabrielli, &amp;amp; Friedman, 2004).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;History and Physical Examination&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Key areas for assessment during the patient's history include onset of symptoms, recent events (e.g., stroke, myocardial infarction [MI], trauma, surgery, bleeding), comorbid illnesses (e.g., hypertension, diabetes, atrial fibrillation, seizures), use of medications (e.g., anticoagulants, insulin, antihypertensives), and substance-abuse history (&lt;strong&gt;Level 3&lt;/strong&gt;; Adams et al., 2007).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Neurological Assessment&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The neurological assessment begins the moment the nurse enters the patient's room. A great deal of neurological assessment can be done unobtrusively by a nurse who is engaged with the patient.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is important to remember that a neurological emergency can occur rapidly, so every contact with a patient with a diagnosis of ischemic stroke, whether as an official examination or not, should consider the patient's neurological status. The patient's level of alertness may vary during the day; however, lethargy may be one of the first signs that the patient's neurological status is declining (Hobdell et al., 2004). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Another important overriding feature of neurological assessment of patients with ischemic stroke is the evaluation of the cranial nerves and examination of bilateral motor ability. The patient should be assessed for visual, tactile and sensory, and motor extinction. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Depending on the setting, the neurological examination may be performed once every hour in the intensive care setting, once every 2 hours in a transitional care unit, and once every 4 hours in a neuroscience unit (&lt;strong&gt;Level 3&lt;/strong&gt;; Hickey, 2003) during the acute phase. Individual hospital units may have differing policies. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Neurological Examination&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The neurological examination begins with assessment of the patient's level of consciousness (LOC). Is the patient alert? Does the patient track the speaker with his or her eyes? Does the patient know his or her name, where he or she is, the date, and, if possible, why he or she is in the hospital?&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;First, the nurse assesses the patient for the least amount of stimulus that is required to arouse him or her. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;As part of general good practice, the patient should be spoken to before he or she is touched. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The nurse should then assess the patient's level of consciousness, basic motor function, and cranial nerves. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The patient should not be asked yes or no questions. The patient may be given a choice of answers, preferably with the wrong answer first. In scoring the National Institutes of Health Stroke Scale (NIHSS) or the modified NIHSS, the first response the patient gives is scored. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The patient may be assessed for alertness and orientation even if he or she is intubated. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To assess cranial nerves II through XII&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Check the pupils for reactivity. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Assess eye movements by having the patient follow an &quot;H&quot; configuration to determine if he or she can move the eyes from side to side and up and down (Hobdell et al., 2004). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Perform a gross examination of the visual fields by facing the patient directly and having him or her look at the examiner's nose. Using the examiner's own peripheral vision, the examiner holds up one or two fingers in the lower and upper quadrants of the patient's left and right sides. The patient must look at the examiner's nose and not directly at the examiner's fingers. The patient's ability to open and close her or his eyes should be noted but not necessarily tested unless there appears to be a problem (Blumenfeld, 2002). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Assess the patient's nasal fold for facial drooping. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Ask the patient to show his or her teeth or to smile. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Ask the patient to stick out the tongue and move it from side to side. Then have the patient press his or her head gently against the nurse's hand to assess for sternomastoid muscle strength. The patient also may shrug the shoulders. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;During motor assessment, the patient may be asked to squeeze and release the examiner's hand with the nonparetic limb. The patient's motor function should then be assessed by determining whether drift is present in the upper limbs when they are extended for 10 seconds (Adams et al., 2003). If the patient is in fairly good neurological condition, the examiner should ask him or her to close the eyes and hold out the hands, as if holding up a pizza, so that upper-extremity strength can be assessed. If the patient's arm slowly drifts down, it is a sign of motor weakness and may be the first subtle sign that the patient is deteriorating neurologically. The patient may then be asked to press the arm against the examiner's hand to be rated for strength on a 0&amp;ndash;5 scale, with 5 being &lt;em&gt;movement against gravity and resistance&lt;/em&gt; and 0 being &lt;em&gt;no movement at all&lt;/em&gt;. The lower extremities may be assessed by having the patient press on the examiner's foot, or to &quot;press on the gas.&quot; The best assessment of motor function is walking (Blumenfeld, 2002). However, this may not always be possible. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If the patient is comatose, movement may be assessed first by his or her response to central pain. The assessment is done by squeezing the shoulder muscles, not by rubbing the sternum because the patient may withdraw from central pain. The next question is whether the patient is able to localize pain, or move away from a painful stimulus in a particular area. This can be assessed by gently squeezing the earlobe. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If the patient is experiencing ataxia, cerebellum function can be tested by having the patient touch the nose. The examiner should then hold out a finger approximately arm's length from the patient at varying places. The patient's ability to move the arm from one place to another in a controlled manner should be observed. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A patient's sensory functioning may be assessed by using a clean testing pin while asking the patient to distinguish between the sharp and dull sides of the pin and asking whether those are &quot;the same or different&quot; on the arms and legs. An alert patient may also be asked if he or she is experiencing any numbness or tingling. A short but thorough neurological assessment of the stroke patient by an experienced practitioner may take approximately 5 minutes. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Assessment Tools&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Several reliable and well-validated scoring systems for initial and serial assessment have been developed for the stroke patient and include the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A widely used tool is the NIHSS (&lt;strong&gt;Level 2&lt;/strong&gt;; Adams et al., 2003; Goldstein, Bertels, &amp;amp; Davis, 1989; Goldstein &amp;amp; Samsa, 1997). An online training program is available for healthcare professionals to learn or review how to administer the NIHSS for acute stroke assessment at &lt;a href=&quot;http://www.strokeassociation.org/presenter.jhtml?identifier=3023009&quot; title=&quot;Stroke Association Web site&quot; target=&quot;_blank&quot;&gt;www.strokeassociation.org/presenter.jhtml?identifier=3023009&lt;/a&gt;. Continuous EEG monitoring has been found to correlate with the NIHSS (Jordan, 2004).&#xD;&#xA;    &lt;p&gt;The NIHSS is a quick and standardized measure of neurological function and stroke severity that ranges from 0 (&lt;em&gt;no deficits&lt;/em&gt;) to 42 (&lt;em&gt;severe deficits&lt;/em&gt;) (&lt;strong&gt;Level 2&lt;/strong&gt;; Goldstein &amp;amp; Samsa, 1997). The NIHSS is a scored assessment tool that identifies neurological deficits including LOC, LOC questions, LOC commands, horizontal-gaze abnormality, visual-field cuts, facial weakness, motor weakness in arms and legs, limb ataxia, sensory loss, aphasia, dysarthria, and extinction or inattention. This tool provides a systematic assessment of the neurological deficits related to stroke and can be used as a measure of patient outcomes. Studies have shown that an increase or decrease of 4 points in the stroke score indicates important changes (Goldstein, 1994). A copy of the NIHSS can be retrieved at &lt;a href=&quot;http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf&quot; title=&quot;NIH Web site&quot; target=&quot;_blank&quot;&gt;www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Barthel Index measures functional capacity, takes 5&amp;ndash;10 minutes to administer, and is highly reliable and valid. Nurses may administer this test to determine disability following a stroke (See Appendix A in the original guideline document). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The modified Rankin scale (see Appendix B in the original guideline document) is the most commonly used endpoint for clinical trials involving stroke. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Interventions, Troubleshooting, and Patient Problems&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Emergent Evaluation&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Time is the most crucial factor for the optimal treatment of an individual who presents with clinical manifestations of a brain attack. The American Heart Association (AHA) and National Stroke Association (NSA) offer consensus statements that help guide the initial care of a patient with an acute stroke (Adams et al., 2007). The recommendations of care are based on recent research indicating that newly discovered therapeutics must be instituted within the first 3&amp;ndash;6 hours to have a positive effect on patient outcomes. Optimal response times for the management of stroke are highlighted below.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Optimal Response Times for Management of a Patient with Acute Stroke&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table width=&quot;50%&quot; border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Optimal Response Times for Management of a Patient with Acute Stroke&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Time&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Goal&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;lt;10 minutes&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Initial patient evaluation performed&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;lt;15 minutes&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Stroke team notified&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;lt;25 minutes&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT scan initiated&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;lt;45 minutes&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CT scan evaluated&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;lt;60 minutes&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Door-to-drug (needle) ensured&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;lt;3 hours&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Patient transferred to inpatient setting&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;2&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: CT = computed tomography. All times are based on the time of arrival of the patient to the emergency department. Information from National Institute of Neurological Disorders and Stroke (Ed.), December 12&amp;ndash;13, 1996, &lt;em&gt;Executive summary: Proceedings of a national symposium on rapid identification and treatment of acute stroke&lt;/em&gt;. Retrieved January 15, 2008, from &lt;a href=&quot;http://www.ninds.nih.gov/news_and_events/proceedings/stroke_proceedings/execsum.htm&quot; title=&quot;NIH Web site&quot; target=&quot;_blank&quot;&gt;www.ninds.nih.gov/news_and_events/proceedings/stroke_proceedings/execsum.htm&lt;/a&gt;.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Prehospital Care&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Individuals within the community must be educated about the clinical signs of brain attack and contacting the Emergency Medical System (EMS [i.e., calling 911 or other applicable telephone number]). Two of the five components of the education performance measures for stroke-center certification are recognizing the signs of stroke and calling 911. EMS personnel must be educated to rapidly recognize stroke signs and emergently evaluate the ABCs (i.e., Airway, Breathing, and Circulation). It is also important to determine the time of onset.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Onset should be determined based on the last time the patient was known to be well or at &quot;baseline.&quot; &quot;Upon awakening&quot; reflects that the time of onset was when the patient went to bed or if he or she had been seen up and well during the night. Time of awakening is not time of onset if symptoms are present upon awakening. If the patient is unresponsive or cannot speak because of aphasia, family members or other observers must be questioned. The treatment generally consists of obtaining vital signs, monitoring cardiac rhythm, establishing intravenous (IV) access, administering supplemental oxygen based upon saturation levels, and notifying the nearest emergency facility of the expected arrival of a possible brain-attack patient. Based on the EMS report, the computed tomography (CT) scanner should be cleared and appropriate staff notified so that they are ready when the patient arrives. If fluids are initiated, normal saline is the fluid of choice.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Hospital Care Emergent Evaluation&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;After the patient arrives in the emergency department (ED), personnel must systematically perform necessary evaluations and diagnostic testing. Patients should be seen by a physician within 10 minutes of arrival, and a stroke team member should be available, at least by telephone, within 15 minutes (&lt;strong&gt;Level 2&lt;/strong&gt;; Alberts et al., 2005). ED personnel initially should evaluate and stabilize the ABCs while taking a brief, comprehensive history. In the initial acute management of the stroke, the goals are to control vital signs, confirm that the event is a stroke, determine the etiology, prevent decompensation and medical complications, and begin appropriate treatment (American Heart Association, 2005).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;After the brief history and physical examination are completed and as soon as the ABCs are stabilized, an emergent CT scan of the brain must be taken. The Brain Attack Coalition recommends that the CT be performed within 25 minutes of arrival to the ED. Results should be available within 20 minutes of completion or within 45 minutes of arrival. The patient's symptoms, neurological examination, and medical examination should help determine the mechanism of stroke and compromised vascular territory.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Acute Management of Acute Ischemic Stroke&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Acute management of an acute ischemic stroke includes the following steps (Adams et al., 2007):&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Monitor airway and ensure that airway equipment is available. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The majority of patients with acute ischemic stroke do not require intubation; however, the risk for respiratory compromise is increased with large infarctions or infarctions that involve the brainstem. Monitor for signs of respiratory compromise and anticipate that the patient's respiratory needs may require intubation. Emergent intubation may be necessary before the stroke outcome is known. Advise the family and help them make decisions about duration of intubation after the outcome is apparent. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Titrate oxygen to maintain oxygen saturation greater than 90% by using pulse oximetry. Respiratory failure can occur when there is brainstem involvement or increased intracranial pressure (ICP). Assessment of the patient's respiratory status includes monitoring respiratory rate, lung auscultation, and continuous oxygen (O&lt;sub&gt;2&lt;/sub&gt;) saturation. Supplemental oxygen of 2&amp;ndash;4 L should be used if the patient is unable to maintain an O&lt;sub&gt;2&lt;/sub&gt; saturation greater than 90%. Arterial blood gases (ABGs) are indicated if the patient is unable to maintain an O&lt;sub&gt;2&lt;/sub&gt; saturation of 90%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Establish intravenous (IV) access. Two sites should be maintained for patients who are candidates for recombinant tissue plasminogen activator (rt-PA) infusion. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Perform STAT (immediate) blood work. A complete blood count and platelet count, prothrombin time (PT)/international normalized ratio (INR) (especially if the patient is on Coumadin and/or to screen for a underlying hematologic [i.e., coagulation] disorder), blood glucose levels, and serum chemistries should be done.&#xD;&#xA;    &lt;p&gt;A cervical spine X-ray is indicated if the patient is unresponsive and the possibility of trauma exists. An electrocardiogram (ECG) should be obtained and, if hypoxia or acute lung disease is suspected, a chest X-ray should be taken.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitor the patient's vital signs, neurological deficits, oxygen saturation, and cardiac rhythm frequently. The patient's cardiac rhythm must be evaluated and treated if abnormalities are found. Cardiac arrhythmias can lead to decreased cardiac output and decreased cerebral perfusion pressure (CPP). A cardioembolic stroke should be suspected, and further investigation is needed if the patient has atrial fibrillation and is not therapeutically anticoagulated or not receiving anticoagulation therapy. An ECG should be performed in the ED to rule out myocardial ischemia. Myocardial infarction is the third leading cause of death for patients with acute stroke, and it is the leading cause of death 30 days after the occurrence of a transient ischemic attack (TIA). ECG changes that mimic myocardial ischemia, such as peaked T waves, are not uncommon in subarachnoid hemorrhage (SAH) and reflect an anterior circulation hemorrhage. Patients with acute stroke should be monitored with telemetry during the first 24 hours of care to detect potentially life-threatening arrhythmias. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Position the patient with the head midline and the head of bed elevated 30 degrees to decrease risk of aspiration and increase cerebral perfusion. If the patient must lie flat, turn the patient on his or her side to minimize aspiration of secretions (Hickey, 2003). Stroke patients can have brainstem lesions that may lead to difficulty swallowing and controlling secretions. In such a situation, intubation should be considered to prevent the risk of aspiration, which can lead to further complications such as pneumonia and atelectasis. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Perform an emergent CT scan to determine whether the patient is a candidate for thrombolytics or other acute interventions. A CT scan without contrast of the brain rapidly excludes hemorrhagic strokes and other causes of neurological dysfunction. If subarachnoid hemorrhage is suspected but no blood or mass effect is seen on CT, cerebrospinal fluid examination should be considered. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitor blood pressure (BP) closely. It is common to see elevated blood pressure during acute stroke. Intervention may not be needed unless BP is &amp;gt;210/110 (See below under &quot;Antithrombolytic Therapy&quot; for BP management prior to rt-PA administration and for post-rt-PA treatment management for treatment parameters). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treat glucose levels higher than 150 mg/dL because elevated glucose levels worsen outcomes (target glucose is 70&amp;ndash;120 mg/dL according to National Institute of Neurological Diseases and Stroke [NINDS] guidelines). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treat temperatures higher than 100 degrees F because increased temperature worsens outcomes. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Although very rare (i.e., incidence of 2%), anaphylactic reactions to rt-PA have been reported, so nurses must be prepared to intervene appropriately if symptoms occur. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Brain attack is a potentially life-threatening event that can have a major effect on the patient and family; it can challenge their beliefs and alter the patient's definition of self. Education and support should start in the ED; a chaplain or minister may be provided if requested, patient and family privacy should be managed, and the patient's modesty should be respected and maintained. In addition, the patient should be given adequate pain relief. Maintenance of the family unit is a desired outcome. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who present with TIAs are at high risk for experiencing a stroke, especially during the week immediately following the TIA. These patients should have an acute ischemic workup and their risk factors should be addressed to minimize their risk of stroke. Symptoms that wax and wane or are relatively nondescript most likely are not secondary to a TIA. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Although seizures are relatively uncommon (accounting for approximately 5% of strokes), they can intensify the brain injury caused by stroke and must be detected and treated in a timely manner. However, for most patients, pharmacological prophylaxis is not indicated. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Neurological and Physical Examination &lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Using the NIHSS, the examiner can perform a neurological examination that can be referenced by all departments of the hospital (see the section &quot;Assessment Tools&quot; above).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If the patient has a change in LOC, the examination should include assessment of pupil size and reactivity. Muscle-tone and reflex testing, along with additional cognition testing, can be done after the CT is completed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If the patient has a decreased LOC, the Glasgow Coma Scale (GCS) can be used to evaluate him or her. Although the GCS score is widely used, it was originally developed to reflect traumatic injury and does not necessarily effectively represent the localized nature of stroke (Weir, Bradford, &amp;amp; Lees, 2003). A copy of the GCS can be retrieved at &lt;a href=&quot;http://www.ssgfx.com/CP2020/medtech/glossary/glasgow.htm&quot; target=&quot;_blank&quot;&gt;www.ssgfx.com/CP2020/medtech/glossary/glasgow.htm&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A complete physical examination should include auscultation of the heart, lungs, and carotid arteries to evaluate for murmurs, crackles, and bruits. Carotid and peripheral pulses should be palpated to evaluate circulation. The head and neck should be inspected for signs of trauma or nuchal rigidity. Nuchal rigidity, ocular hemorrhage, coma, and papilledema may be indicative of SAH, infections, tumors, or metabolic abnormalities (Hobdell et al., 2004).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Laboratory Evaluation&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;STAT blood work should be completed within 30 minutes of arrival to the ED and include complete blood cell count with differential, platelet count, PT, partial thromboplastin time (PTT), INR, electrolytes, creatinine, blood urea nitrogen, and blood glucose (&lt;strong&gt;Level 3&lt;/strong&gt;; Goldstein, 2007). A pregnancy test may be indicated with the STAT labs for females of childbearing age. The patient's lipid profile (fasting) should be assessed within the first 24 hours but is not necessary during the emergent workup. Routine full chemistry, urinalysis, and cardiac enzymes should be done only if indicated. If the cause of the stroke cannot be established based on initial laboratory and radiographic evaluation, optional laboratory tests can be performed to screen for unusual causes of stroke.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Radiographic Evaluation&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A CT without contrast to rule out hemorrhage should be performed immediately after the patient has been stabilized (Adams et al., 2007). All subsequent therapy and medical management depend on the results of the CT scan. An ischemic stroke or edema generally does not show up on the CT scan for 12&amp;ndash;24 hours unless the patient has had a large infarction. Intracerebral hemorrhage greater than 1 cm can immediately be identified in the parenchyma. CT scans diagnose more than 95% of SAHs (Morgenstern et al., 1998), suggesting an aneurysm when blood is visualized in the subarachnoid space. Repeat CT scans are rarely needed during hospitalization unless there is clinical deterioration in the patient. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The use of CT angiography (CTA) and CT perfusion (CTP) is growing in popularity and usefulness for acute stroke management. CTA/CTP imaging at admission assists in evaluating the cervical vessels and determining infarct localization and site of vascular occlusion. As this technology improves and is studied further, the use of CTA and CTP may increase. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A chest radiograph should be obtained in the ED or after the patient is admitted to the stroke center or neuroscience unit. A baseline chest film is necessary to rule out pneumonia, the second most common cause of death in stroke, and to evaluate the size of the heart (Bravata et al., 2007). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Magnetic resonance imaging (MRI) is not recommended for emergency diagnosis of a stroke for several reasons, including critical time loss within the 3-hour window and availability of personnel and equipment, particularly outside academic centers (Adams et al., 2003). In addition, patient conditions such as agitation or decreased LOC may preclude an MRI (Singer et al., 2004). However, MRI's diagnostic accuracy has been shown to be superior to that of CT (Chalela et al., 2007; Schellinger &amp;amp; Fiebach, 2005). Modern multisequence stroke-MRI protocols are an emerging routine for the assessment of stroke and may eventually replace CT (Adams et al., 2005; Fiebach et al., 2004). However, among currently available imaging technology, CT remains superior in its ability to detect the presence of blood. New techniques such as diffusion and perfusion-weighted MRIs can delineate infarcted brain tissue and areas of hypoperfusion. Patients who are at excessive risk for bleeding may be excluded from thrombolytic therapy based on MRI. MRI may be used to guide rt-PA therapy beyond the 3-hour window (Schellinger, Fiebach, &amp;amp; Hacke, 2003). Many institutions obtain an MRI 24 hours after the initial stroke to &quot;localize&quot; the stroke, and the use of CTA is increasing. Because of increased bony artifact in the posterior fossa, MRI/magnetic resonance angiography (MRA) are also the preferred tests for brainstem or cerebellum stroke (Solenski, 2004). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For a definitive diagnosis of an aneurysm and its anatomical location, arteriography (or angiography) is indicated, especially if blood is seen in the subarachnoid space on the CT scan. A decision can be made at that time about whether the patient is a candidate for treatment of the aneurysm with ballooning, coil placement, or surgical clipping. Invasive-testing arteriography may be performed emergently if 3&amp;ndash;6 hours have elapsed since the onset of stroke symptoms. Arteriography is used to diagnose stenosis or acute vascular thrombotic occlusions of large and small blood vessels in the head and neck. If a radiologist specializing in neurointerventional procedures is available to perform acute revascularization with thrombolytics, the blood supply can be restored, the size of the infarct minimized, and the neurological deficit immediately improved. Angiography also allows for clot retrieval in centers that can perform this procedure. If an underlying stenosis is producing the ischemic event, a cerebral balloon angioplasty can be performed. If the patient is past the 3&amp;ndash;6 hour window of opportunity, the arteriography may be scheduled at a more optimal time. At that point, arteriograms are performed to evaluate whether the patient has a stenosis of the carotid artery that requires surgery. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Noninvasive tests for the workup for causes of ischemic stroke are discussed as follows:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Carotid duplex scanning is the standard test used to initially screen for anterior stroke or patients with suspected cervical internal carotid stenosis. Differentiation between 95% and 100% occlusion is not possible, but demonstration of stenosis exceeding 60% is highly accurate. However, CTA of the cervical vessels or magnetic resonance angiography may be used in place of carotid duplex scanning in some institutions. If a high-grade stenosis is demonstrated, a cerebral angiography should be done before a carotid endarterectomy is performed. Before an angiography is performed, it should be determined whether the patient is a surgical candidate. The angiography is the best tool to accurately evaluate the surface characteristics of the artery. Individuals are considered at high risk for stroke if ulcerated plaques are identified. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;In addition to a basic echocardiogram, a transesophageal echocardiography (TEE) should be included in the workup if the source of stroke is suspected to be cardioembolic or if the ECG is inconclusive. Patients with a history of cardiac disease, recent MI, and atrial fibrillations are at high risk of having an atrial thrombi. A TEE is sensitive for detecting apical thrombi as well as atrial septal defects or patent foramen ovales that may be the cause of the stroke. Before the TEE is performed, it must be determined whether the patient is a candidate for long-term anticoagulation or a surgical candidate for treatment of any cardiac lesions. The transthoracic echocardiography is sensitive only to ventricular thrombi and therefore generally is used for stroke patients only to evaluate their ventricular function. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Acute Pharmacological Management of Ischemic Stroke&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;An acute brain attack must be viewed as an evolving, dynamic process. The stroke event results from an infarct evolves over time. Recent research has shown that a window of opportunity exists for salvaging brain tissue. This information has led researchers to develop new treatments that may halt the progression of ischemic tissue to infarcted tissue. Three distinct strategies have emerged in an effort to acutely treat stroke: (a) urgent revascularization to restore perfusion to ischemic tissue, (b) protection of neurons from the ischemia, and (c) blocking the cascade of reperfusion injury. Before the recent research, pharmacological therapy focused only on the use of anticoagulants for prevention of further thrombotic events or antiplatelet therapy to prevent the formation of thrombus.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Antithrombolytic Therapy&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Thrombolytic drugs work on recently formed thrombi by converting fibrin-bound plasminogen to plasmin. Plasmin is a natural fibrinolytic agent that lyses clots by breaking down fibrinogen and fibrin. Thrombolytic drugs typically are not effective on older thrombi because of the extensive fibrin polymerization that has occurred.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Tissue-type plasminogen activators are found principally in vascular endothelial cells. Because their activity is enhanced in the presence of fibrin, they have been described as clot specific despite the fact that they have some general systemic effects.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Inclusion and Exclusion Criteria for rt-PA (Activase)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Inclusion&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Treatment should only be initiated within 3 hours of symptom onset.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Exclusion of intracranial hemorrhage through cranial computed tomography (CT) scan or other method sensitive for detecting hemorrhage&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exclusion&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Evidence of intracranial hemorrhage on pretreatment evaluation&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Suspicion of subarachnoid hemorrhage&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recent intracranial surgery, serious head trauma, or recent, previous stroke&lt;/p&gt;&#xD;&#xA;&lt;p&gt;History of intracranial hemorrhage&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Uncontrolled hypertension at time of treatment (e.g., &amp;gt;185 mm Hg systolic or &amp;gt;110 mm Hg diastolic)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Seizure at the onset of stroke&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Active internal bleeding&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Intracranial neoplasm, arteriovenous malformation, or aneurysm&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Known bleeding diathesis including but not limited to:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Current use of oral anticoagulants (e.g., warfarin sodium) with prothrombin time (PT) &amp;gt;15 seconds, international normalized ratio (INR) &amp;gt;1.7 &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Heparin administered within 48 hours preceding the onset of stroke and elevated activated partial thromboplastin time (aPTT) at presentation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Platelet count &amp;lt;100,000/mm &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Risks of rt-PA (Activase) therapy for treating acute ischemic stroke may be increased in the following conditions and should be weighed against the anticipated benefits, which include:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Severe neurological deficit (e.g., National Institutes of Health Stroke Scale [NIHSS] &amp;gt;22) at presentation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Major early infarct signs on CT scan (e.g., substantial edema, mass effect, or midline shift) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Full prescribing and dosing information is available at &lt;a href=&quot;http://www.activase.com/utilities/pi.jsp&quot; target=&quot;_blank&quot;&gt;www.activase.com/utilities/pi.jsp&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Current guidelines for the administration of intravenous rt-PA in acute stroke are based on the original NINDS study protocol and medication insert. Based on the efficacy of the NINDS phase 2B safety trial, a definitive phase 3 trial was not pursued. Therefore, the protocol contains some idiosyncrasies that were not intended for inclusion in the FDA package insert. Because these criteria were not intended for clinical use, a physician's judgment is required for individual cases (Mohr et al., 2004). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients must present within the 3-hour window of stroke onset. Thrombolytic therapy needs to be initiated within this time window (&lt;strong&gt;Level 1&lt;/strong&gt;; NINDS rt-PA Stroke Study Group, 1995). Outcomes are better when the medication is administered within 90 minutes of symptom onset. Hospitals should aim at infusing rt-PA within 60 minutes of the patient's presentation (Adams et al., 2005). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Thrombolysis should be implemented only when a physician with expertise in stroke establishes a diagnosis of ischemic stroke and a physician with appropriate expertise in reading this type of study assesses the brain CT (&lt;strong&gt;Level 1&lt;/strong&gt;; Adams, et al., 2007). The clinical diagnosis of ischemic stroke should include a measurable neurological deficit and should be based on an acceptable stroke-severity scale such as the NIHSS. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Glucose and platelet counts should be reviewed for all patients before drugs are administered. If there is no clinical history suggesting coagulopathy, rt-PA administration should not have to wait until the INR and PTT results are available. Pregnancy, blood alcohol, and toxicology screens should be reviewed for certain patients. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;BP at the time of administration should be equal to or below 185/110 mm Hg without aggressive antihypertensive therapy. Treatment options for BP include the following:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Labetalol bolus of 10&amp;ndash;20 mg over 1&amp;ndash;2 minutes; if there is inadequate response within 10&amp;ndash;20 minutes, an additional dose may be administered &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Nitropaste 1&amp;ndash;2 inches &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;While eligibility for rt-PA is being determined, rt-PA should be prepared for likely candidates to avoid wasting time. Genentech, the manufacturer of rt-PA, reimburses facilities for unused portions of the drug. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A total dose of 0.9 mg/kg of rt-PA is given, not to exceed a maximum dose of 90 mg. The first 10% of the dose is given as an IV bolus over 1 minute, and the remaining dose (90%) is given as an IV drip over the following hour (Minematsu, 2006). rt-PA should be diluted 1:1 in sterile water or normal saline, and the mixture should be gently swirled. If the patient's weight is not known and cannot be quickly ascertained from self-report or by other means such as prior records, two healthcare workers should independently estimate the patient's weight, and the resulting average estimate should be used as the approximate weight for drug administration. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Do not administer aspirin, heparin, or warfarin until 24 hours after rt-PA infusion and then only after the follow-up head CT or other, similar imaging has been performed. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The patient should be evaluated for any inclusions and exclusions prior to administration of rt-PA, which are provided in Figure 2 in the original guideline document. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Two IV lines should be established before drug initiation. Use isotonic saline and avoid glucose solutions. Use of central lines, arterial punctures, and nasogastric tubes should be restricted during the first 24 hours. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If there is a question about whether the patient will be able to void, a urinary catheter should be inserted before infusion or held until at least 30 minutes after infusion. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The patient and family should be educated about the benefits and possible complications of rt-PA infusion, particularly the risk of bleeding. Consents are not required for standard IV rt-PA therapy unless dictated by specific hospital policy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Follow-up CT or MRI should be ordered for 24 hours (plus or minus 6 hours) after rt-PA administration. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;After rt-PA administration, the patient should be admitted to an intensive care unit for 24 hours or to a dedicated stroke unit where he or she can be monitored appropriately. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Post-rt-PA blood pressure should be maintained at or below 180 mg Hg systolic and/or 105 mg Hg diastolic for 24 hours. Options for hypertensive management include the following:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Labetalol, 10 mg IV push over 1&amp;ndash;2 minutes. The dosage may be repeated and/or doubled every 10 minutes, up to 100 mg in one period of treatment or 300 mg per day. An alternative is to give 10 mg IV followed by an infusion at 2&amp;ndash;8 mg per minute, up to 300 mg per day. Caution must be used for patients with asthma, chronic obstructive pulmonary disease, left ventricular failure, second- or third-degree heart block, and in patients with a heart rate &amp;lt;50 beats per minute (Adams et al., 2007). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Nicardipine, 5 mg per hour IV infusion as initial dose, titrated to desired effect by increasing 2.5 mg per hour every 5 minutes to a maximum dose of 15 mg per hour (Adams et al., 2007). Caution must be used for patients with left ventricular failure, aortic stenosis, and cardiac ischemia. Nicardipine is usually the next drug of choice after labetalol (Adams et al., 2007). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Sodium nitroprusside, IV infusion, 0.25&amp;ndash;10 mcg/kg&lt;sup&gt;-1&lt;/sup&gt; per minute&lt;sup&gt;-1&lt;/sup&gt; IV may be used if other agents are ineffective or if hypertension is extreme. Caution must be used for patients with elevated ICP, coronary artery disease, and renal insufficiency (Adams et al., 2007). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Other options include hydralazine 10&amp;ndash;20 mg IV or enalaprilat 0.625 mg IV every 6 hours. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In addition, hypotension should be avoided to maintain adequate perfusion pressure. Clinical hypotension should be treated to achieve a target mean arterial pressure of 120&amp;ndash;130 mm Hg. The underlying cause of hypotension is treated with the use of fluid boluses and titration of a neo-synephrine drip (i.e., 0.5&amp;ndash;3 mcg/kg per minute). Caution must be used with patients with congestive heart failure, coronary artery disease, or renal insufficiency (Adams et al., 2007). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients must be monitored closely for complications. Based on the NINDS protocol, neurological assessment and blood pressure should be checked every 15 minutes for the first 2 hours, every 30 minutes for the next 6 hours, and then every hour for the next 16 hours (Adams et al., 2007). &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Potential Complications of rt-PA Therapy&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;There are several potential complications of rt-PA therapy. They include the following:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Intracranial Hemorrhage&#xD;&#xA;    &lt;p&gt;Intracranial hemorrhage risk is highest during rt-PA infusion because rt-PA has a short half-life (i.e., 5&amp;ndash;7 minutes). However, the risk of intracranial hemorrhage remains for 24&amp;ndash;36 hours after infusion. If the patient develops severe headache, acute hypertension, nausea, vomiting, drowsiness, or neurological deterioration on examination, an intracranial hemorrhage should be suspected. Notify the physician, discontinue the infusion (but not unless another cause of the neurological deterioration is apparent), and obtain a STAT CT scan (or other test sensitive for the presence of blood). Draw blood for PT, PTT, platelet count, fibrinogen, and type and cross. Prepare for administration of 6&amp;ndash;8 units of cryoprecipitate-containing factor VIII or 6&amp;ndash;8 units of platelets. Remind the physician to alert the neurosurgeon or hematologist.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Angioedema&#xD;&#xA;    &lt;p&gt;Monitor the patient for angioedema. Angioedema occurs in 1%&amp;ndash;2% of all patients with acute stroke treated with rt-PA. It occurs more commonly in patients taking angiotensin-converting enzyme inhibitors and usually starts toward the end of the rt-PA infusion. Nursing staff should begin to examine the tongue 20 minutes before IV administration and repeat the examination several times until 20 minutes postinfusion. If angioedema is suspected, immediately consider discontinuation of the rt-PA, give 50 mg of diphenhydramine (Benadryl) IV and ranitidine 50 mg or famotidine 20 mg IV. If the tongue continues to enlarge after the Benadryl and ranitidine/famotidine, give 80&amp;ndash;100 mg IV of methylprednisolone (Solu-Medrol). If there is further increase in angioedema, epinephrine 0.1% 0.3 ml subcutaneously or 0.5 mg by nebulizer may be indicated. The patient may require intubation. If the tongue is too large for safe orotracheal intubation, prepare for a fiberoptic nasotracheal intubation or tracheostomy.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bleeding (nonbrain)&#xD;&#xA;    &lt;p&gt;In addition to neurological assessment, the nurse must assess for signs of internal bleeding, such as tachycardia, a decrease in BP, pallor, or restlessness. Minor bleeding complications include oozing from catheter-insertion, venipuncture, or intramuscular sites; gingival bleeding; hemoptysis; superficial hematoma; ecchymosis; and purpura. All body secretions should be tested for occult blood (&lt;strong&gt;Level 1&lt;/strong&gt;; NINDS rt-PA Stroke Study Group, 1995).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Because stroke is an unexpected, acute event, the patient and family may be anxious during this time, so constant reassurance and explanation of interventions and assessments may help reduce stress and anxiety.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Intra-arterial Thrombolysis&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Many stroke centers are able to administer rt-PA intra-arterially (IA-tPA). Although this therapy is not FDA approved and is considered experimental, off-label use for acute ischemic stroke is common and may be considered for patients who arrive after the 3-hour window (&lt;strong&gt;Class I&lt;/strong&gt;, &lt;strong&gt;Level 2&lt;/strong&gt;; Adams et al., 2007) and who can be treated within a 6-hour window after stroke onset (&lt;strong&gt;Class II&lt;/strong&gt;, &lt;strong&gt;Level 3&lt;/strong&gt;; Adams, et al., 2007). IA-tPA is generally considered for patients with a NIHSS =10. Another common, appropriate approach is combination therapy. This approach is used for patients with moderate-to-severe stroke (i.e., NIHSS =10). A low dose of IV rt-PA (0.6 mg/kg) is administered and is followed by IA therapy (up to 22 mg).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Mechanical Thrombolysis&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Merci&lt;sup&gt;&amp;reg;&lt;/sup&gt; Retriever was FDA approved in 2004 and the Penumbra System was approved in 2008 for treatment of acute ischemic stroke patients who are not rt-PA candidates or who have failed IV rt-PA therapy up to 8 hours after stroke onset. The devices are also an option for anticoagulated or postoperative patients who are not candidates for IV rt-PA and for patients with large clots that are resistant to IV rt-PA therapy (&lt;strong&gt;Level 2&lt;/strong&gt;; Adams et al., 2007; Bose et al., 2008).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Oral Antiplatelet Therapy&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Aspirin therapy at an initial dose of 325 mg orally is now recommended for most patients within 24&amp;ndash;48 hours of stroke onset (&lt;strong&gt;Level 1&lt;/strong&gt;; Adams et al., 2007; Bose et al., 2008).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Patient Problems&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Initial Treatment Concerns&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The initial plan for the management of a patient with acute stroke is to control vital signs, prevent deterioration of the patient, and prevent medical complications of the stroke that worsen the patient's outcome. Medical complications include respiratory failure, hypertension, hyperglycemia, cerebral edema, and fever. The nurse caring for the patient must coordinate the activities of an interdisciplinary team to provide high-quality care to the stroke patient. The critical path, clinical guidelines, and physician order sets provide a guide to the interdisciplinary team for managing the care of patients with complex presentations. Issues addressed on the critical-care path include patient assessment, diagnostic tests, medications, treatments, mobility and nutrition needs, bowel and bladder care, deep venous thrombosis (DVT) prevention, interdisciplinary consultations necessary for optimal stroke care, and the psychosocial care and teaching needed for the patient and family prior to discharge (California Acute Stroke Pilot Registry Investigators, 2005; Kavanagh, Connolly, &amp;amp; Cohen, 2006; Kwan &amp;amp; Sandercock, 2004).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Vital Signs and Neurological Assessment&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;After the patient is admitted to the hospital, vital signs and neurological assessment should be scheduled every 1&amp;ndash;2 hours for the first 8 hours.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Arrhythmia&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The patient should be monitored on cardiac telemetry for the first 24 hours after a stroke (&lt;strong&gt;Level 2&lt;/strong&gt;; Adams et al., 2007). Telemetry can be discontinued after 24 hours if no arrhythmias have been detected. If telemetry is unavailable, a Holter monitor can be used to evaluate for arrhythmias. Atrial fibrillation is commonly first detected at the time of the stroke. The nurse must monitor for arrhythmias and evaluate the patient's hemodynamic status. Many stroke patients have underlying cardiac problems and are at risk for an acute MI during the acute stages of a stroke. The patient may need to have an evaluation by a cardiologist during the acute stages of the stroke.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Oxygenation&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;An oxygen saturation monitor should be used to evaluate the patient's oxygenation. The patient should be placed on oxygen 2&amp;ndash;4 L per minute and titrate to maintain an oxygen saturation of &lt;span style=&quot;text-decoration: underline;&quot;&gt;&amp;gt;&lt;/span&gt;92%. An ABG test should be performed and a chest film taken if a saturation of &lt;span style=&quot;text-decoration: underline;&quot;&gt;&amp;gt;&lt;/span&gt;92% cannot be obtained (&lt;strong&gt;Level 3&lt;/strong&gt;; Adams et al., 2007).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Aspiration/Swallowing&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;At the time of the stroke or during the acute stages of a stroke, patients may not be able to clear secretions and could be at high risk for aspiration. Aspiration can result in respiratory compromises due to infection or pulmonary edema. Nurses must frequently auscultate lungs, evaluate for signs of respiratory compromise, and evaluate for signs of dysphagia to prevent the occurrence of aspiration pneumonia. Initial interventions may include elevating the head of the bed (HOB) or turning the patient on his or her side, monitoring the patient during oral intake, and obtaining a formal swallowing evaluation if symptoms of choking are noted. Nurses must do a bedside swallowing assessment prior to the institution of any oral intake, including medications. (See section &quot;Intracranial Pressure/Edema&quot; below for HOB effects on cerebral blood flow.)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Blood Pressure&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;It is important to monitor BP frequently during the acute stages of a stroke. BP &amp;gt;160 is present in 60% of patients with an acute stroke (Adams et al., 2007). The brain raises the CPP to enhance blood flow to the damaged tissue. Aggressive use of antihypertensives can decrease the blood flow to the viable tissue surrounding the infarction and worsen the neurological deficits. The elevated BP generally declines by 28% within the first 24 hours, even without medication. BP should be decreased by 15%&amp;ndash;25% during the first 24 hours. Overaggressive use of antihypertensive agents or calcium antagonists can decrease CPP dangerously. IV or oral labetalol, intravenous enalapril, or nicardipine are the recommended drugs for BP management (&lt;strong&gt;Level 3&lt;/strong&gt;; Adams et al., 2007).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Nipride should be avoided or used cautiously; because it causes cerebral vasodilation, it may lead to increased ICP (Rose &amp;amp; Mayer, 2004). Nurses must monitor BP frequently during the first 24 hours because patients are at highest risk for hypertension during that period (Braimah et al., 1997). Because increased BP is likely, the nurse must evaluate whether the increase is acceptable or due to causative factors such as hypoxia, increased ICP due to hemorrhagic transformation or herniation, full bladder, or pain. It may be necessary to notify the physician concerning antihypertensive medication if the BP remains elevated. Receiving BP parameters regarding the timing of pharmaceutical intervention is helpful. The nurse should check BP when the patient is in both lying and sitting positions before asking him or her to stand for the first time. If the patient is not a candidate for rt-PA, do not lower BP unless it is &amp;gt;220/120 (&lt;strong&gt;Level 2&lt;/strong&gt;; Adams et al., 2007).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Serum Glucose&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Monitoring serum blood glucose levels is important during the acute stages of ischemic stroke. Hypoglycemia may lead to neurological deficits that mimic a stroke and should be promptly treated if present. According to the AHA guidelines, a glucose &amp;lt;50 is an exclusion indicator to rt-PA. Hypoglycemia, although rare in patients with acute stroke, should be treated with dextrose 50% as needed (&lt;strong&gt;Level 2&lt;/strong&gt;; Adams et al., 2007).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Hyperglycemia is seen in two-thirds of all acute strokes (Lindsberg &amp;amp; Roine, 2004). The mechanism is poorly understood, but evidence has shown that hyperglycemia worsens the clinical outcome because of the increased anaerobic metabolism, lactic acidosis, and free-radical production. Because infarct expansion, hemorrhagic transformation and reduced recanalization with thrombolytics, poor clinical outcome, and increased length of stay have been associated with elevated glucose, hyperglycemia should be avoided (&lt;strong&gt;Level 2&lt;/strong&gt;; Baird et al., 2003; Bruno et al., 2002; Els et al., 2002; Williams et al., 2002).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recent evidence-based clinical data have shown that management of serum glucose during the first 24 hours is a priority. Blood glucose &amp;gt;200 mg/dL was found to be an independent indicator of volume expansion in ischemic strokes and poorer neurological outcomes. According to the 2007 AHA guidelines, target blood glucose should be &amp;lt;140 mg/dL (&lt;strong&gt;Level 3&lt;/strong&gt;; Adams et al., 2007). Alvarez-Sab&amp;iacute;n and colleagues (2004) found that the only predictor of outcome at 3 months was a blood glucose &amp;gt;140 mg/dL. Strict glucose control is possible with continuous insulin infusion or sliding-scale insulin. Also, IV solutions high in glucose or hypotonic solutions should not be used.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;IV administration of glucose-containing solutions should be avoided. A patient's blood glucose should be maintained in the &amp;lt;140 mg/ dL range. A serum glucose range of 140&amp;ndash;185 mg/dL should be treated with IV insulin (&lt;strong&gt;Level 3&lt;/strong&gt;; Adams et al., 2007).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Intracranial Pressure/Edema&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Patients with middle cerebral artery (MCA) occlusion are at highest risk of increased ICP, which peaks approximately 4 days after the acute stroke. Cerebral edema rarely occurs during the first 24 hours after an ischemic stroke unless the stroke is a large multilobar or cerebellar infarct. Also, younger patients who generally have no cerebral atrophy are at higher risk of developing cerebral edema.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Signs and symptoms of increasing intracranial pressure are as follows:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Early signs are decreased LOC (e.g., restlessness, confusion, change in orientation), headache, and visual disturbances. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Late signs are pupillary abnormalities, changes in BP (e.g., widening pulse pressure), heart rate (e.g., bradycardia), or changes in respiratory pattern with changes in ABGs. Respiratory patterns vary according to the area of the brain that is involved. The lower pons and medulla have regulatory centers, or automatic respiration. Strokes in these centers cause changes in the breathing patterns. These patterns include Cheyne- Stokes (in the cerebral hemisphere), central neurogenic hyperventilation (in the midbrain), apneusis (in the pons), cluster (in the pons or medulla), and ataxia (Lee et al., 1976). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The goals of brain-edema management are to reduce ICP while maintaining CPP and to prevent the occurrence of brain herniation. The patient should be monitored and treated for hypoxemia, hypercarbia, and hyperthermia (&lt;strong&gt;Level 1&lt;/strong&gt;; Adams et al., 2007). Immediate treatment includes hyperventilation; osmotic, cerebral spinal-fluid drainage; and decompressive surgery. The goal of hyperventilation management is to decrease the carbon dioxide concentration by 5&amp;ndash;10 mm Hg, which lowers the ICP by 25%&amp;ndash;30%. Hyperventilation should be done only on a short-term basis because brain perfusion may be compromised as vasoconstriction occurs (&lt;strong&gt;Level 2&lt;/strong&gt;; Adams et al., 2007). The nurse may frequently assess the patient neurologically to monitor for changes in brain perfusion. Osmotic diuretics such as furosemide or mannitol are recommended for treatment of cerebral edema. Mannitol can be given every 6 hours. The nurse must closely monitor serum and urine osmolality (&lt;strong&gt;Level 2&lt;/strong&gt;; Adams et al., 2007).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If hydrocephalus is present, drainage of fluid through an intraventricular catheter can rapidly reduce the ICP. The two remaining treatment options for increased ICP are surgical decompression and evacuation of a large infarcted area (i.e., hemicraniectomy). Large cerebellar infarctions that compress the brainstem are best treated with surgical decompression. An evacuation may be done in patients with large hemispheric infarcts, but patients who survive these events, especially older patients and those with dominant infarctions, have severe residual neurological deficits (Kilincer et al., 2005). The timing for performing this procedure is unclear; some prefer to perform it within 24 hours of the malignant edema (Schwab et al., 1998). Large cerebellar infarcts can lead to brainstem compression and hydrocephalus. Suboccipital craniotomy can be performed to prevent herniation and relieve pressure from the hydrocephalus (Chen, Lee, &amp;amp; Wei, 1992; Mathew et al., 1995; Rieke et al., 1993). Randomized clinical trials continue, and recent studies have shown less favorable outcomes than prior studies (Fandino et al., 2004). The morbidity is unknown concerning surgical treatment for malignant edema of the cerebral hemisphere. Treatment may be life saving, but the patient's outcome may include survival with severe disability (&lt;strong&gt;Level 2&lt;/strong&gt;; Chen, Lee &amp;amp; Wei, 1992; Fandino et al, 2004.; Mathew et al., 1995; Rieke et al, 1993; Schwab et al., 1998).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The AHA guidelines do not recommend corticosteroids for treating cerebral edema in patients with a stroke (&lt;strong&gt;Level 1&lt;/strong&gt;; Adams et al., 2007; Bauer &amp;amp; Tellez, 1973; Mulley, Wilcox, &amp;amp; Mitchell, 1978; Norris &amp;amp; Hachinski, 1986).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If signs and symptoms of increasing intracranial pressure are noted, the nurse should conduct a thorough neurologic assessment; the physician should be notified; an emergent CT scan should be performed; and airway, breathing, and circulation should be maintained.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;General measures for preventing elevation of ICP include the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;HOB elevation should be 30 degrees or according to practitioner specification; however, recent studies have found that in patients with MCA stroke, a head-flat position increased blood flow to the brain via transcranial Doppler technology (Wojner-Alexander et al., 2005) and ICP/CPP monitoring (Schwarz et al., 2002). These findings have not been incorporated into AHA stroke guidelines and have not yet been widely adopted nationally. For patients with MCA stroke, the neurological benefits of horizontal (i.e., flat) positioning should be weighed against the potential risk of aspiration (&lt;strong&gt;Level 2&lt;/strong&gt;; Schwarz et al., 2002; Wojner-Alexander et al., 2005) regarding the effect of HOB positioning on cerebral blood flow that examine benefits versus potential risk of aspiration is warranted (&lt;strong&gt;Level 3&lt;/strong&gt;; Panel Consensus). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Good head/body alignment prevents increased intrathoracic pressure and allows for venous drainage. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Good pain control should be provided on a consistent basis. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Activities should be diffused to prevent overtiring or overstimulating the patient. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Normothermia should be maintained. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Temperature Should Be Monitored&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Temperature elevation has been associated with increased mortality and morbidity in an acute stroke. The fever increases metabolic demands of the brain, which can worsen the ischemia and lead to further tissue damage. Fever following an acute stroke may be due to infection or may be neurogenic. The patient should be treated with antipyretic agents and other cooling measures, evaluated for pneumonia and urinary tract infection, and treated accordingly. Research is studying the use of hypothermia for acute stroke and head injury, but data supporting its use are insufficient. The 2007 AHA guidelines recommend keeping the patient normothermic (&lt;strong&gt;Level 2&lt;/strong&gt;; Adams et al., 2007). Antipyretics should be used to lower body temperature in febrile patients until further studies are completed (&lt;strong&gt;Level 3&lt;/strong&gt;; Adams et al., 2007).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Seizures&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Seizures are a potential complication of stroke and, if not controlled, can be potentially life threatening. Seizures can occur at the time of the acute stroke or during the first few days or several months after the event. No study has specifically tested the usefulness of anticonvulsant medications for preventing or controlling seizures following stroke. Drugs that have been proven valuable for preventing seizures due to other causes, however, are recommended for patients who have had one or more seizures after a stroke. The routine prophylactic administration of anticonvulsants to stroke survivors who have not had seizures is not recommended (&lt;strong&gt;Level 3&lt;/strong&gt;; Adams et al., 2007).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If anticonvulsant medication is required, the nurse must assess the patient's cognitive ability and readiness to learn. The nurse must educate the patient and family about the seizure condition, pharmacological management, and regular medication regimen for treatment of seizures. The patient must be advised never to adjust or take additional medications without consulting the physician.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Some patients may never experience a seizure or may have a seizure after being discharged from the hospital. With this in mind, patients and families should be educated about the risk of seizure because it could occur several months after the stroke.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;General Supportive Care of a Patient with Stroke&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Medical and nursing management must focus on prevention of subacute complications of a stroke. Such complications can include malnutrition, aspiration pneumonia, urinary tract infection (UTI), bowel or bladder dysfunction, DVT, pulmonary embolism, contractures, joint abnormalities, pressure ulcers, and depression.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Fluid Management and Nutrition&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Fluid Management&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Fluid management is crucial for the patient with acute stroke; both volume overload and depletion should be avoided. As with fluid overload, dehydration is associated with a less favorable outcome and is a common problem (Mohr et al., 2004). Dehydration may be preexisting and related to the cause of the acute prothrombotic event, associated with treatment delay, or may be due to difficulties with swallowing, resulting in unbalanced hydration needs. Patients who have difficulty with communication, cognitive problems, decreased mobility, or an infection or who are receiving diuretic therapy or are hyperthermic are also at risk. Critically ill stroke patients may also suffer from more complex electrolyte disturbances, such as the syndrome of inappropriate antidiuretic hormone or cerebral salt-wasting syndrome (for a review of signs and symptoms, see Dooling &amp;amp; Winkelman, 2004), and, in rare cases, diabetes insipidus.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Intravenous therapy with isotonic fluids, such as Ringer 's solution or normal saline, should be instituted and continued for at least the first 24 hours after the acute prothrombotic event. Fluid balance during the first 24 hours should be more or less positive, depending on the level of dehydration on admission (Mohr et al., 2004). Hydration should be assessed by clinical observation; fluid intake and output, serum hematocrit, osmolarity, and sodium, as well as urine osmolarity, should be evaluated. In critically ill patients, fluid disturbances can be further assessed with central venous pressure measurements or pulmonary capillary wedge pressure via a pulmonary catheter.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Nutrition&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Nutritional compromise interferes with stroke recovery.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A swallow assessment should be performed as soon as possible after admission to the hospital and no later than 48 hours after admission. Patients suspected of having swallowing problems should be given nothing by mouth until after a structured bedside swallowing assessment is performed (&lt;strong&gt;Level 2&lt;/strong&gt;; Adams et al., 2007). Nutrition should be initiated within 48&amp;ndash;72 hours after the swallowing assessment.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;It is suggested that enteral, rather than parenteral, nutrition be pursued in critically ill patients. The enteral route has several advantages, including simpler application, lower risk of infection, utilization of the normal physiological functions of digestion and absorption, maintenance of the intestinal mucosa, and lower cost (Mohr et al., 2004). Intestinal function and motility (as manifested by bowel sounds and aspiration of gastric residual) must be regularly monitored and, if necessary, supported by a stimulant such as metoclopramide. If motility is not restored or if dysphagia is expected to continue for more than 6&amp;ndash;8 weeks, postpyloric feeding via a percutaneous endoscopic gastrostomy (PEG) should be considered. Parenteral nutrition is indicated in cases of imminent intubation or operation, gastrointestinal leakage, ileus, pancreatitis, and other conditions in which a patient's gastrointestinal tract is unable to tolerate oral or enteral feedings for at least 5 to 7 days (Mohr et al., 2004).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Dysphagia&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Nurses must monitor patients for clinically observable signs of dysphagia that include coughing or choking on saliva or food, pocketing of food in the mouth, garbled speech, facial muscle weakness, delayed or absent swallow reflex, drooling, watery eyes after any intake, or gurgling voice. Clinically observable signs of aspiration are not always evident because stroke patients can be &quot;silent aspirators.&quot; Patients at highest risk include those with infarctions in the brainstem, large hemispheric lesions, multiple strokes, or decreased LOC.&#xD;&#xA;    &lt;p&gt;Clinical interventions after the initial nursing swallow screen include consulting the speech and language pathologist (SLP) for formal evaluation and further recommendations on diet or techniques for decreasing the risk of aspiration. Also, nurses should perform aggressive oral care. Minimizing the bacterial count in the mouth can decrease the risk of developing aspiration pneumonia if the patient aspirates (&lt;strong&gt;Level 2&lt;/strong&gt;; Abe et al., 2006; Ferozali, Johnson, &amp;amp; Cavagnaro, 2007).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When the patient is determined to be at risk for aspiration, nurses must alert the physician or nurse practitioner to request a formal dietary consultation from a registered dietitian so that the patient's metabolic and nutritional needs can be evaluated. Malnutrition has been proven to delay recovery and to increase the duration of hospital stay. However, nutritional supplements are not routinely recommended (&lt;strong&gt;Level 2&lt;/strong&gt;; Adams et al., 2007). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tests to evaluate for dysphagia include bedside videofluoroscopic and endoscopic studies. Videofluoroscopic procedures include barium esophagram and modified barium swallow. The patient is asked to swallow different textures of food coated with barium, and then he or she is watched for any aspiration. These tests must be conducted with fluoroscopy in the radiology department. Endoscopic studies include flexible endoscopic evaluation of swallowing (FEES) and flexible endoscopic evaluation of swallowing with sensory testing. These tests allow direct visualization of the laryngopharyngeal structure while the patient is given a variety of dyed food textures and consistencies. Both tests are used to evaluate for pooling, spillage, endotracheal penetration, and aspiration. The FEES test is popular because of its portability for patients in the intensive care unit (Tabaee et al., 2006).&#xD;&#xA;    &lt;p&gt;After these tests, the radiologist and SLP can make recommendations for safe food and liquid consistency. Patients who are aspirating or are at risk for aspiration with all types of food and liquids should receive nutrition through a soft feeding tube until swallowing is feasible. Alternatively, nutrition can be provided via a PEG if long-term feeding is anticipated.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;The dietitian can help determine the exact caloric needs and the correct commercially prepared formula. The dietitian follows the patient during the rehabilitation and adjusts his or her caloric needs as necessary.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Most patients can tolerate an oral diet but may need to be taught special techniques, such as specific ways of positioning the head and neck and specified swallowing maneuvers. In addition, changes in consistency of food may be necessary during the acute phase of the stroke (&lt;strong&gt;Level 2&lt;/strong&gt;; Huang et al., 2006; Ramsey, Smithard, &amp;amp; Kalra, 2003). Weight should be monitored at least once weekly to assess for adequacy of nutrition (&lt;strong&gt;Level 3&lt;/strong&gt;; CPG Panel Consensus).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;An SLP will develop a feeding plan to decrease the risk of aspiration. Basic principles for preventing aspiration include the following:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The patient should be placed in a high Fowler's position, preferably seated in a chair, for the meal and should remain seated for at least 30 minutes after the meal. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Mouth care should be performed prior to feeding because it can facilitate sensation and the production of saliva, which in turn can facilitate swallowing. Mouth care also should be performed after eating to observe whether the patient is pocketing food. Food fragments retained in the patient's mouth can lead to aspiration. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The patient or care provider should be instructed to place the foods into the unaffected side of the patient's mouth. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pulmonary status should be assessed after eating. Suctioning apparatus should be kept near the patient at all times for possible use, and the patient should be monitored closely during his or her first meal. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Families must be educated about the feeding plan and the required special techniques for decreasing the risk of aspiration. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;p&gt;In addition, patients should be fed small portions and allowed ample time for chewing and swallowing. Use of the chin-tuck method can help minimize aspiration during swallowing. Avoid allowing a patient to drink thin fluid from a straw while lying flat in bed; this is a dangerous feeding practice that can increase the risk of aspiration. Straws should be removed from the room and the family instructed not to give the patient a drink with a straw under the aforementioned circumstance. Nurses must be aware of whether the patient has a visual-field cut, because he or she may eat only the items on one side of the plate. Patients must be instructed to visually scan their meal tray and plate (&lt;strong&gt;Level 3&lt;/strong&gt;; Barker, 2007).&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Risk of Infection&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Airway and oxygenation should be monitored closely, and a structured swallowing assessment has been shown to be the best way to decrease the incidence of pneumonia in cases of acute stroke (&lt;strong&gt;Level 2&lt;/strong&gt;; Hinchey et al., 2005). Patients with suspected pneumonia or UTI should be treated with antibiotics (&lt;strong&gt;Level 1&lt;/strong&gt;; Adams et al., 2007). Two additional, nurse initiated interventions that have been shown to decrease the incidence of pneumonia are (a) initiation of early mobility and (b) good pulmonary toileting (&lt;strong&gt;Level 2&lt;/strong&gt;; Hilker et al., 2003).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Stroke patients are at risk for a higher incidence of UTI because of changes in sphincter control and frequent use of an indwelling catheter. If at all possible, placement of indwelling catheters should be avoided because of this risk (&lt;strong&gt;Level 3&lt;/strong&gt;; Adams et al., 2007). A change in a patient's LOC should lead to suspicion of a UTI if there are no other reasons for neurological deterioration. Urinalysis and cultures should be obtained if a UTI is suspected (Adams et al., 2007; Roth et al., 2001).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Bowel and Bladder Care&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Bowel and bladder dysfunction can lead to skin breakdown, UTIs, decreased self-esteem, depression, and interference with the progress of rehabilitation. The nurse must be responsible for evaluating the patient's bowel and bladder routine and coordinating a retraining program that meets the needs of individual patients.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Constipation is the most common bowel problem after a stroke, and to date virtually no interventional studies have been conducted in this important area. The nurse must assess for bowel sounds and abdominal distension and evaluate the patient's fluid intake and hydration status. Nurses also should assess the patient's premorbid bowel-elimination pattern. If, prior to the stroke, the patient usually had bowel movements in the morning, it would be ideal to attempt to duplicate this pattern; the use of medications may be necessary in this situation. The patient should be evaluated for impaction every 2 days. A bowel program for preventing constipation can integrate the use of stool softeners, laxatives, suppositories, digital stimulation, and enemas. Stool softeners should be given daily beginning with the acute phase. A laxative is necessary if the patient has not had a bowel movement for 2 days. At the end of the second day, it is ideal to give a laxative that requires 6&amp;ndash;8 hours to work, after which bowel care should be attempted again in the morning. An enema should be used as a last resort if the laxative, suppository, or digital stimulation is ineffective after the third day. The nurse must assume the responsibility for requesting the medications or developing a bowel program protocol or set of orders (&lt;strong&gt;Level 1&lt;/strong&gt;; Harari et al., 2004).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;AHA guidelines recommend avoiding indwelling catheters or, if they are medically necessary, they should be removed as soon as possible because of the increased risk of infection (see &quot;Risk of Infection&quot; section above). Indwelling catheters should not be placed for the convenience of nursing care. After the indwelling catheter is removed, intermittent catheterization may be necessary to retrain the bladder. A bladder scanner can be used to evaluate post-void residuals (PVRs) and determine whether catheterization is necessary. The goal is to simulate normal physiological filling and emptying. If the PVR is &amp;gt;100, intermittent catheterization is recommended. This should also help to decrease the incidence of UTIs (&lt;strong&gt;Level 3&lt;/strong&gt;; Chan, 1997).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Daily intake and output should be monitored. The patient should be offered a commode, bedpan, or urinal every 2 hours during waking hours and every 4 hours at night. The patient should be taken to the bathroom regularly during the night or be encouraged to use a bedside commode at night to decrease the risk of falling. Also, if there are fluid restrictions, the nurse may encourage greater fluid intake during the day and decreased fluid intake during the evening before bedtime (&lt;strong&gt;Level 3&lt;/strong&gt;; North American Nursing Diagnosis Association, 2007).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Risk of Pulmonary Embolism and Deep Vein Thrombosis&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Following a stroke, patients are at risk for development of thrombophlebitis or DVT in the weak or paralyzed lower extremity. The DVT risk is related to both the paralysis of the leg and the immobility caused by the stroke. If the patient is unable to ambulate, passive range of motion or active range of motion can be started during the first 24 hours poststroke. Patients should be positioned to minimize the occurrence of dependent edema. Joint guidelines published by the ASA and the American Academy of Neurology recommend that subcutaneous unfractionated heparin, low-molecular-weight heparin (LMWH), and heparinoids may be considered for DVT prophylaxis for at-risk patients with acute ischemic stroke, but the guidelines also acknowledge the lack of demonstrable benefit in the treatment of pulmonary embolism (&lt;strong&gt;Level 1&lt;/strong&gt;; Adams et al., 2007; Coull et al., 2002). The guidelines' authors caution that the relative benefits of these drugs must be weighed against the risk of hemorrhage. A recent meta-analysis reviewed the use of compression and pneumatic devices for DVT prevention for intensive-care patients. The conclusion of the review was that no significant difference existed among results obtained from three patient treatments: (a) no treatment, (b) treatment with LMWH, or (c) treatment with compression or mechanical devices (&lt;strong&gt;Level 1&lt;/strong&gt;; Limpus et al., 2006). Compression devices should be used if anticoagulants are contraindicated (&lt;strong&gt;Level 2&lt;/strong&gt;; Adams et al., 2007). If hemorrhage is a concern in the acute stroke, prophylactic prevention should include the use of bilateral-sequential compression devices. In addition, the most effective prevention of DVT is early mobilization of the patient. Early mobilization not only decreases the risk of DVT but also lessens the likelihood of major complications such as pneumonia and decubitus ulcers (Adams et al., 2007).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Mobility and Musculoskeletal System&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Immobility can lead to contractures, orthopedic complications, atrophy, and nerve-pressure palsies. Nursing interventions, including range-of-motion and positioning techniques, can prevent joint contractures and atrophy. Nurses must assess for special deformities that may be found on the affected side, including shoulder adduction; flexion contractures of the hand, wrist, and elbow; external rotation of the hip; and plantar flexion of the foot. Subluxation of the affected shoulder is common. Nurses should take special care to avoid pulling on the affected arm and shoulder when repositioning patients in bed or from a lying to a sitting or standing position. Subluxation may not be preventable; however, careful positioning and movement of the affected arm may prevent the development of a painful shoulder-hand syndrome. Nurses can implement passive range-of-motion exercises during the first 24 hours or instruct patients and their families to perform active range-of-motion exercises to prevent contractures and other orthopedic complications. The rehabilitation team (i.e., physical and occupational therapists) should be consulted soon after the acute stroke to develop a plan of care for rehabilitation and to determine whether the patient has any special adaptive-equipment needs (&lt;strong&gt;Level 3&lt;/strong&gt;; Adams et al., 2007).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Skin Care&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Stroke patients are at risk for skin breakdown because of loss of sensation and impaired circulation. Approximately 9% of all hospitalized patients develop pressure ulcers. The stroke patient is the most at risk because of dependence in mobility and incontinence; also, many stroke patients have associated diabetes, peripheral vascular disease, and end-stage renal failure (Berlowitz et al., 2001).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A reliable risk-assessment tool such as the Braden scale can be used initially to evaluate and predict the risk of pressure-ulcer development. Nursing measures include repositioning the patient, turning the patient every 2 hours, using proper transfer techniques to avoid excessive friction that can lead to skin injury or tears, using skin-care products on the patient, and keeping the patient's skin clean and dry (&lt;strong&gt;Level 3&lt;/strong&gt;; Duncan, 2005).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Depression&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Depression is common among stroke patients. The depression is not always the result of the patient's sadness about his or her deficits or loss of previous lifestyle but is often is the result of chemical and physical changes in the brain. Studies have shown that patients with left frontal infarcts are 70% more likely to become depressed than those who experience similar devastating injuries (Ross &amp;amp; Rush, 1981).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The nurse is in an excellent position to notice symptoms of depression and ask the physician to order an appropriate referral or consider pharmacological management. Sometimes the depression occurs after hospitalization, so before the patient is discharged the nurse should educate the patient and family to recognize signs and symptoms of depression. Depression has been shown to have an impact on mobility and activities of daily living (ADL) after acute stroke (van de Port et al., 2006).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Stroke patients can experience a syndrome termed &lt;em&gt;involuntary emotional expression disorder&lt;/em&gt; (IEED). IEED causes patients to cry or laugh involuntarily. The syndrome is common among patients with neurological disorders but is frequently underrecognized and undertreated. Because nurses are the healthcare providers who spend the most time with the patient, they should be aware of this syndrome. When IEED exists, the nurse should notify the physician and assist with pharmacological treatment. In addition, the patient may need psychological counseling for education and self-care strategies. The nurse, too, can educate the patient and the family about management of IEED (&lt;strong&gt;Level 3&lt;/strong&gt;; Robinson-Smith &amp;amp; Grill, 2007).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Neurological Deficits&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Neurological findings during the acute phase of stroke and throughout the course of recovery direct the patient's needs during medical management, direct rehabilitation efforts, and guide the nursing plan of care. Neurological impairments include altered LOC; cognitive deficits in higher functions, memory, and ability to learn; motor deficits; disturbances in balance and coordination; somatosensory deficits; disorders of vision; unilateral neglect; speech and language disorders (e.g., dysphagia); and affective disorder. Disturbances in consciousness are a strong predictor of adverse outcomes after stroke. They are more likely when brain damage is extensive and especially if the brainstem is involved or increased ICP is present. In such cases, positioning the patient in the lateral or semiprone position helps ensure airway maintenance. An inability to clear secretions increases the risk of aspiration, so patients generally require pharyngeal suctioning.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Disorders in higher brain functions are common after stroke. The patient's ability to acquire and retain new information can be determined by observing the patient's interaction with other persons; responses to questions on orientation, current events, and memory of the stroke; and ability to perform arithmetic and simple tests of recall. Communication difficulties may be mistaken for cognitive disorders. A patient's cognitive deficits may interfere with rehabilitation efforts. Nursing interventions should include:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Frequent orientation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Activities divided into short steps &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Protection from injury &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Repeated instructions as necessary &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Realistic, attainable goals &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Removal of excessive distractions in the patient's environment &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Motor deficits reflect the type, location, and extent of vascular lesion. Motor deficits may be isolated or associated with sensory, cognitive, or speech deficits. The most common motor deficits are weakness and paralysis, but discoordination, clumsiness, involuntary movements, or abnormal posturing may also be identified. Motor deficits influence ADL and rehabilitation efforts.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Infarctions of the cerebellum or vestibular system can produce disturbances in balance and coordination. Discoordination without motor or sensory loss is identified as ataxia. Assessment of the patient's ability to perform finger-to-nose, heel-to-shin, or alternating-movement tests can determine the presence of ataxia. The patient may exhibit limb, gait, or truncal ataxia.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Somatosensory deficits can manifest as numbness, tingling, abnormal sensations (i.e., dysesthesia), or excessive reactions to sensory stimuli (i.e., hyperesthesia). Profound sensory loss interferes with the rehabilitation of motor impairments. The most common visual disorder is homonymous hemianopia. Visual disorders include visual-field defects, conjugate-gaze paralysis, or diplopia. Severe visual disturbances increase the complexity of rehabilitation. Unilateral neglect refers to a patient's lack of awareness of a specific part of the body or the external environment. Unilateral neglect generally occurs after right-hemisphere strokes. Patients with this disorder ignore sensory stimuli in the left part of the environment. Patients with severe unilateral neglect may deny the problems that arise as a result of the stroke or may not recognize their own body parts. When such patients are asked to describe a complex picture, they ignore items in their left visual field and ignore sensory stimuli on their left. Bedside evaluation finds the patient's head turned toward the right, and the patient often ignores examiners on the left side. Patients with unilateral neglect may wash or bathe only one side of the body. The patient's safety must be the immediate concern of all involved in his or her care. Patients are at risk of falling because they deny that they have motor deficits and are unaware of physical structures that are within their perceptual space.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Communication disorders occur in as many as 40% of stroke patients. Aphasia is seen most often after vascular events in the language-dominant hemisphere and leads to disturbances in comprehension, speech, verbal expression, reading, and writing. Dysarthria and apraxia of speech should be differentiated from aphasia. Dysarthria may be due to dysfunction of the larynx, pharynx, palate, tongue, lips, or mouth. It is an impairment of speech due to slow or weak muscle coordination. Patients who have apraxia of speech are, despite the absence of motor deficits, unable to program the sequence of volitional movements that are required for producing sounds of speech.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;It is important to consult the rehabilitation team, including the physiatrist, physical and occupational therapists, and SLP, to evaluate the patient for rehabilitation needs as soon as the patient is admitted (&lt;strong&gt;Level 3&lt;/strong&gt;; Panel Consensus). The rehabilitation team can be involved in developing a plan of care to address all of the patient's neurological deficits. Their evaluation is needed to determine the next level of care before discharge. In addition, the social worker (SW) or case manager must be consulted to help the family choose an appropriate rehabilitation center or nursing care facility as needed. In addition, the SW can answer questions concerning financial issues.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Patient and Family Education&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For the stroke patient, rehabilitation begins immediately. Recovery following stroke occurs over several months to years and is possible at all ages. Education targeting reduction of risk factors for future stroke may include smoking cessation and management of chronic disease, such as hypertension, diabetes, and coronary heart disease. Encouraging family involvement, including their understanding and participation in the plan of care, is extremely important. Participation can include supporting the patient in risk-factor management and rehabilitation therapies for regaining physical function as well as providing psychosocial support.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Important points on which to educate the patient and family are the signs of stroke and the importance of calling 911 to obtain immediate medical attention. The American Stroke Association (&lt;a href=&quot;http://www.strokeassociation.org/&quot; title=&quot;ASA Web site&quot; target=&quot;_blank&quot;&gt;www.strokeassociation.org&lt;/a&gt;) and the NSA (&lt;a href=&quot;http://www.stroke.org/&quot; title=&quot;Stroke Web site&quot; target=&quot;_blank&quot;&gt;www.stroke.org&lt;/a&gt;) have excellent Web sites that can serve as resources for the nurse, patient, and family. Key areas of education for patients in the stroke population, their significant others, and caretakers include the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;What is a stroke? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Is my stroke ischemic or hemorrhagic? &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Signs and symptoms of a stroke &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;What to do to prevent a future stroke&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Medications: dosages, reason for taking, and side effects &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;BP management &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Activity &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Diet &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Monitoring and follow-up &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Common complications&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Dysphagia &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Skin breakdown &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Urinary and/or bowel incontinence &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Behavior changes &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Contractures &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Seizures &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Depression &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;What's next?&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Rehabilitation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Recovery/prognosis&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Hemiplegia/hemiparesis &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Sensory loss &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Communication issues (related to aphasia) &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Documentation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In the ED, documentation should include the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Time of onset &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Symptoms &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Vital signs, including BP, pulse rate and rhythm, respiration, oxygen saturation, temperature, and blood glucose &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Neurological assessment, including NIHSS score, level of physical functioning, LOC, and muscle strength &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Time of laboratory tests and electrocardiogram &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Time of radiological testing such as CT scan and chest X ray &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Time of thrombolytics administration &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Swallowing evaluation, including assessment of swallowing before solids or liquids are given by mouth &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Documentation during and after administration of rt-PA should include monitoring of vital signs and neurological status every 15 minutes for 2 hours, then every 30 minutes for 6 hours, and then every hour for 16 hours (note systolic blood pressure &amp;gt;185 or diastolic blood pressure &amp;gt;110; Adams et al., 2007).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Ongoing documentation should include the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Neurological assessment, including level of physical functioning, level of cognition, muscle strength, and cranial-nerve findings. (Some physicians prefer that the nurse describe &quot;what they saw&quot; rather than report that a certain cranial nerve is not functioning.) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Vital signs, including BP, pulse rate and rhythm, respiration, oxygen saturation, and temperature &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Input and output &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Swallowing ability &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mechanism of communication &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Activity level &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Skin integrity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psychosocial issues &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient and family education &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Discharge planning &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Data Quality Classification&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class I&lt;/strong&gt;: Randomized controlled trial without significant limitations or meta-analysis&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class II&lt;/strong&gt;: Randomized controlled trial with important limitations (e.g., methodological flaws, inconsistent results); observational study (e.g., cohort, case control)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class III&lt;/strong&gt;: Qualitative study, case study, or series&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IV&lt;/strong&gt;: Evidence from reports of expert committees and/or expert opinion of the guideline panel, standards of care, and clinical protocols that have been identified&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level 1&lt;/strong&gt;: Recommendations are supported by class I evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level 2&lt;/strong&gt;: Recommendations are supported by class II evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level 3&lt;/strong&gt;: Recommendations are supported by class III and class IV evidence.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="98" OrdBy="605" ID="425" Name="References Supporting the Recommendations" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Abe S, Ishihara K, Adachi M, Okuda K. Oral hygiene evaluation for effective oral care in preventing pneumonia in dentate elderly. Arch Gerontol Geriatr. 2006 Jul-Aug;43(1):53-64. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16271775&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Adams H, Adams R, Del Zoppo G, Goldstein LB. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke. 2005 Apr;36(4):916-23. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15800252&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Adams HP Jr, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR, Hademenos GJ. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003 Apr;34(4):1056-83. [402 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12677087&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EFM, American Heart Association, American Stroke Association Stroke Council, Clinical Cardiology Council. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology [trunc]. Stroke. 2007 May;38(5):1655-711. [738 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17431204&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Alberts MJ, Latchaw RE, Selman WR, Shephard T, Hadley MN, Brass LM, Koroshetz W, Marler JR, Booss J, Zorowitz RD, Croft JB, Magnis E, Mulligan D, Jagoda A, O'Connor R, Cawley CM, Connors JJ, Rose-DeRenzy JA, Emr M, Warren M, Walker MD, Brain Attack Coalition. Recommendations for comprehensive stroke centers: a consensus statement from the  Brain Attack Coalition. Stroke. 2005 Jul;36(7):1597-616. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15961715&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Alvarez-Sabin J, Molina CA, Ribo M, Arenillas JF, Montaner J, Huertas R, Santamarina E, Rubiera M. Impact of admission hyperglycemia on stroke outcome after thrombolysis: risk stratification in relation to time to reperfusion. Stroke. 2004 Nov;35(11):2493-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15472110&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Heart Association. American Heart Association guidelines for cardiopulmonary resuscitation and  emergency cardiovascular care. Part 9: adult stroke. Circulation. 2005 Dec 13;112(24 Suppl):IV111-20.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Baird TA, Parsons MW, Phanh T, Butcher KS, Desmond PM, Tress BM, Colman PG, Chambers BR, Davis SM. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke. 2003 Sep;34(9):2208-14. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12893952&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Barker E. Neuroscience nursing. 3rd ed. St. Louis (MO): Mosby; 2007. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bauer RB, Tellez H. Dexamethasone as treatment in cerebrovascular disease. 2. A controlled study in acute cerebral infarction. Stroke. 1973 Jul-Aug;4(4):547-55. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4579369&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Berlowitz DR, Brandeis GH, Anderson JJ, Ash AS, Kader B, Morris JN, Moskowitz MA. Evaluation of a risk-adjustment model for pressure ulcer development using the Minimum Data Set. J Am Geriatr Soc. 2001 Jul;49(7):872-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11527477&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Blumenfeld H. Neuroanatomy through clinical cases. Sunderland (MA): Sinauer Associates; 2002. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bose A, Henkes H, Alfke K, Reith W, Mayer TE, Berlis A, Branca V, Sit SP, for the Penumbra Phase 1 Stroke Trial Investigators. The Penumbra System: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol. 2008 Aug;29(7):1409-13. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18499798&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Braimah J, Kongable G, Rapp K, Daley S, Bratina P, Sailor S, Barch C, Donnarumma R, Spilker J. Nursing care of acute stroke patients after receiving rt-PA therapy. The NINDS rt-PA Stroke Study Group. J Neurosci Nurs. 1997 Dec;29(6):373-83. [18 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9479659&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bravata DM, Ho SY, Meehan TP, Brass LM, Concato J. Readmission and death after hospitalization for acute ischemic stroke: 5-year follow-up in the medicare population. Stroke. 2007 Jun;38(6):1899-904. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17510453&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bruno A, Levine SR, Frankel MR, Brott TG, Lin Y, Tilley BC, Lyden PD, Broderick JP, Kwiatkowski TG, Fineberg SE, NINDS rt-PA Stroke Study Group. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002 Sep 10;59(5):669-74. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12221155&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;California Acute Stroke Pilot Registry Investigators. The impact of standardized stroke orders on adherence to best practices. Neurology. 2005 Aug 9;65(3):360-5. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16087898&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Chalela JA, Kidwell CS, Nentwich LM, Luby M, Butman JA, Demchuk AM, Hill MD, Patronas N, Latour L, Warach S. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet. 2007 Jan 27;369(9558):293-8. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17258669&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Chan H. Bladder management in acute care of stroke patients: a quality improvement project. J Neurosci Nurs. 1997 Jun;29(3):187-90. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9220366&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Chen HJ, Lee TC, Wei CP. Treatment of cerebellar infarction by decompressive suboccipital craniectomy. Stroke. 1992 Jul;23(7):957-61. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1615544&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaturvedi S, Johnston KC, Starkman S, Morgenstern LB, Wilterdink JL, Levine SR, Saver JL. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Neurology. 2002 Jul 9;59(1):13-22. [19 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12105302&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Dooling E, Winkelman C. Hyponatremia in the patient with subarachnoid hemorrhage. J Neurosci Nurs. 2004 Jun;36(3):130-5. [25 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15233412&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Duncan PW, Zorowitz R, Bates B, Choi JY, Glasberg JJ, Graham GD, Katz RC, Lamberty K, Reker D. Management of Adult Stroke Rehabilitation Care: a clinical practice guideline. Stroke. 2005 Sep;36(9):e100-43. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16120836&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Els T, Klisch J, Orszagh M, Hetzel A, Schulte-Monting J, Schumacher M, Lucking CH. Hyperglycemia in patients with focal cerebral ischemia after intravenous thrombolysis: influence on clinical outcome and infarct size. Cerebrovasc Dis. 2002;13(2):89-94. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11867881&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Fandino J, Keller E, Barth A, Landolt H, Yonekawa Y, Seiler RW. Decompressive craniotomy after middle cerebral artery infarction. Retrospective analysis of patients treated in three centres in Switzerland. Swiss Med Wkly. 2004 Jul 24;134(29-30):423-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15389353&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ferozali F, Johnson G, Cavagnaro A. Health benefits and reductions in bacteria from enhanced oral care. Spec Care Dentist. 2007 Sep-Oct;27(5):168-76. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17990475&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Fiebach JB, Schellinger PD, Gass A, Kucinski T, Siebler M, Villringer A, Olkers P, Hirsch JG, Heiland S, Wilde P, Jansen O, Rother J, Hacke W, Sartor K, Kompetenznetzwerk Schlaganfall B5. Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke. 2004 Feb;35(2):502-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14739410&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH stroke scale. Arch Neurol. 1989 Jun;46(6):660-2. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2730378&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Goldstein LB, Samsa GP. Reliability of the National Institutes of Health Stroke Scale. Extension to non-neurologists in the context of a clinical trial. Stroke. 1997 Feb;28(2):307-10. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9040680&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Goldstein LB. Acute ischemic stroke treatment in 2007. Circulation. 2007 Sep 25;116(13):1504-14. [94 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17893286&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Goldstein LB. Sample size calculations for clinical trials using the NIH Stroke Scale. Stroke. 1994 Aug;25(8):1700-1. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8042225&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Harari D, Norton C, Lockwood L, Swift C. Treatment of constipation and fecal incontinence in stroke patients: randomized controlled trial. Stroke. 2004 Nov;35(11):2549-55. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15486330&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hickey J. The clinical practice of neurological and neurosurgical nursing. 5th ed. Philadelphia (PA): Lippincott, Williams and Wilkins; 2003. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hilker R, Poetter C, Findeisen N, Sobesky J, Jacobs A, Neveling M, Heiss WD. Nosocomial pneumonia after acute stroke: implications for neurological intensive  care medicine. Stroke. 2003 Apr;34(4):975-81. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12637700&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hinchey JA, Shephard T, Furie K, Smith D, Wang D, Tonn S, Stroke Practice Improvement Network Investigators. Formal dysphagia screening protocols prevent pneumonia. Stroke. 2005 Sep;36(9):1972-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16109909&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hobdell EF, Stewart-Amidei C, McNair N, Blissitt P, Dowling G, Mastick J, et al. Assessment. In: Bader MK, Littlejohns LR, editor(s). AANN core curriculum for neuroscience nursing. 4th ed. St. Louis (MO): Elsevier; 2004. p. 115-73.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Huang JY, Zhang DY, Yao Y, Xia QX, Fan QQ. Training in swallowing prevents aspiration pneumonia in stroke patients with dysphagia. J Int Med Res. 2006 May-Jun;34(3):303-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16866025&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Jordan KG. Emergency EEG and continuous EEG monitoring in acute ischemic stroke. J Clin Neurophysiol. 2004 Sep-Oct;21(5):341-52. [64 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15592008&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kavanagh D, Connolly P, Cohen J. Promoting evidence-based practice: implementing the American Stroke Association's acute stroke program. J Nurs Care Qual. 2006 Apr-Jun;21(2):135-42. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16540782&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kilincer C, Asil T, Utku U, Hamamcioglu MK, Turgut N, Hicdonmez T, Simsek O, Ekuklu G, Cobanoglu S. Factors affecting the outcome of decompressive craniectomy for large hemispheric  infarctions: a prospective cohort study. Acta Neurochir (Wien). 2005 Jun;147(6):587-94; discussion 594. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15739038&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kwan J, Sandercock P. In-hospital care pathways for stroke. In: Cochrane Database of Systematic Reviews [internet]. Issue 4. Hoboken (NJ): John Wiley &amp; Sons, Ltd.; 2004&amp;nbsp;[Art. No.: CD002924]. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Layton AJ, Gabrielli A, Friedman WA, editor(s). Textbook of neurointensive care. Philadelphia (PA): Elsevier; 2004. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lee MC, Klassen AC, Heaney LM, Resch JA. Respiratory rate and pattern disturbances in acute brain stem infarction. Stroke. 1976 Jul-Aug;7(4):382-5. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=960158&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Limpus A, Chaboyer W, McDonald E, Thalib L. Mechanical thromboprophylaxis in critically ill patients: a systematic review and meta-analysis. Am J Crit Care. 2006 Jul;15(4):402-10; quiz/discussion. [42 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16823018&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lindsberg PJ, Roine RO. Hyperglycemia in acute stroke. Stroke. 2004 Feb;35(2):363-4. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14757880&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mathew P, Teasdale G, Bannan A, Oluoch-Olunya D. Neurosurgical management of cerebellar haematoma and infarct. J Neurol Neurosurg Psychiatry. 1995 Sep;59(3):287-92. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7673958&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Minematsu K. Recent advances in acute stroke management [abstract]. In: International congress series: functional and molecular imaging of stroke and dementia: updates in diagnosis, treatment, and monitoring; Japan, 1290.2006 Jun. p. 25-9.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mohr JP, Choi DW, Grotta JC, Weir B, Wolf PA. Stroke: pathophysiology, diagnosis, and management. 4th ed. Philadelphia (PA): Churchill Livingstone; 2004. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Morgenstern LB, Luna-Gonzales H, Huber JC Jr, Wong SS, Uthman MO, Gurian JH, Castillo PR, Shaw SG, Frankowski RF, Grotta JC. Worst headache and subarachnoid hemorrhage: prospective, modern computed tomography and spinal fluid analysis. Ann Emerg Med. 1998 Sep;32(3 Pt 1):297-304. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9737490&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mulley G, Wilcox RG, Mitchell JR. Dexamethasone in acute stroke. Br Med J. 1978 Oct 7;2(6143):994-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=361156&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Norris JW, Hachinski VC. High dose steroid treatment in cerebral infarction. Br Med J (Clin Res Ed). 1986 Jan 4;292(6512):21-3. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3080050&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;North American Nursing Diagnosis Association (NANDA). Alteration in patterns of urinary elimination: incontinence. In: NANDA, editor(s). Nursing diagnoses: definitions and classification, 2007-2008. Philadelphia (PA): North American Nursing Diagnosis Association (NANDA); 2007. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ramsey DJ, Smithard DG, Kalra L. Early assessments of dysphagia and aspiration risk in acute stroke patients. Stroke. 2003 May;34(5):1252-7. [57 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12677020&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rieke K, Krieger D, Adams HP, Aschoff A, Meyding-Lamade U, Hacke W. Therapeutic strategies in space-occupying cerebellar infarction based on clinical, neuroradiological, and neurophysiological data. Cerebrovasc Dis. 1993;3:45-55.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Robinson-Smith G, Grill JD. Recognizing involuntary emotional expression disorder. J Neurosci Nurs. 2007 Aug;39(4):202-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17847666&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rose JC, Mayer SA. Optimizing blood pressure in neurological emergencies. Neurocrit Care. 2004;1(3):287-99. [93 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16174926&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ross ED, Rush AJ. Diagnosis and neuroanatomical correlates of depression in brain-damaged patients. Implications for a neurology of depression. Arch Gen Psychiatry. 1981 Dec;38(12):1344-54. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7316678&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Roth EJ, Lovell L, Harvey RL, Heinemann AW, Semik P, Diaz S. Incidence of and risk factors for medical complications during stroke rehabilitation. Stroke. 2001 Feb;32(2):523-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11157192&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Schellinger PD, Fiebach JB, Hacke W. Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke. 2003 Feb;34(2):575-83. [92 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12574579&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Schellinger PD, Fiebach JB. Perfusion-weighted imaging/diffusion-weighted imaging mismatch on MRI can now be used to select patients for recombinant tissue plasminogen activator beyond 3 hours: pro. Stroke. 2005 May;36(5):1104-5. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15790944&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Schwab S, Steiner T, Aschoff A, Schwarz S, Steiner HH, Jansen O, Hacke W. Early hemicraniectomy in patients with complete middle cerebral artery infarction. Stroke. 1998 Sep;29(9):1888-93. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9731614&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Schwarz S, Georgiadis D, Aschoff A, Schwab S. Effects of body position on intracranial pressure and cerebral perfusion in patients with large hemispheric stroke. Stroke. 2002 Feb;33(2):497-501. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11823659&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Singer OC, Sitzer M, du Mesnil de Rochemont R, Neumann-Haefelin T. Practical limitations of acute stroke MRI due to patient-related problems. Neurology. 2004 May 25;62(10):1848-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15159492&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Solenski NJ. Transient ischemic attacks: Part I. Diagnosis and evaluation. Am Fam Physician. 2004 Apr 1;69(7):1665-74. [25 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15086038&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Tabaee A, Johnson PE, Gartner CJ, Kalwerisky K, Desloge RB, Stewart MG. Patient-controlled comparison of flexible endoscopic evaluation of swallowing with sensory testing (FEESST) and videofluoroscopy. Laryngoscope. 2006 May;116(5):821-5. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16652095&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995 Dec 14;333(24):1581-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7477192&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;van de Port IG, Kwakkel G, van Wijk I, Lindeman E. Susceptibility to deterioration of mobility long-term after stroke: a prospective cohort study. Stroke. 2006 Jan;37(1):167-71. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16322486&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Weir CJ, Bradford AP, Lees KR. The prognostic value of the components of the Glasgow Coma Scale following acute  stroke. QJM. 2003 Jan;96(1):67-74. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12509651&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Williams LS, Rotich J, Qi R, Fineberg N, Espay A, Bruno A, Fineberg SE, Tierney WR. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology. 2002 Jul 9;59(1):67-71. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12105309&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wojner-Alexander AW, Garami Z, Chernyshev OY, Alexandrov AV. Heads down: flat positioning improves blood flow velocity in acute ischemic stroke. Neurology. 2005 Apr 26;64(8):1354-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15851722&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified for selected recommendations (see the &amp;quot;Major Recommendations&amp;quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Reduced death and disability that may result from a stroke through prompt recognition of stroke signs and symptoms, initiation of appropriate response efforts, and provision of interventions and education for preventing stroke complications and subsequent stroke&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Potential complications of recombinant tissue plasminogen activator (rt-PA) therapy include:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Intracranial hemorrhage &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Angioedema &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Bleeding (nonbrain)&lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Excessive effects and complications may result from blood pressure management. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hyperventilation may compromise brain perfusion. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Surgical treatment for malignant edema may result in severe disability. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bladder catheterization may result in urinary tract infections.&lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Exclusion criteria for recombinant tissue plasminogen activator (rt-PA) therapy:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Evidence of intracranial hemorrhage on pretreatment evaluation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Suspicion of subarachnoid hemorrhage &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recent intracranial surgery, serious head trauma, or recent, previous stroke &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;History of intracranial hemorrhage &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Uncontrolled hypertension at time of treatment (e.g., &amp;gt;185 mm Hg systolic or &amp;gt;110 mm Hg diastolic) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Seizure at the onset of stroke &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Active internal bleeding &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Intracranial neoplasm, arteriovenous malformation, or aneurysm &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Known bleeding diathesis including but not limited to:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Current use of oral anticoagulants (e.g., warfarin sodium) with PT &amp;gt;15 seconds, INR &amp;gt;1.7 &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Heparin administered within 48 hours preceding the onset of stroke and elevated aPTT at presentation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Platelet count &amp;lt;100,000/mm&lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Risks of rt-PA (Activase) therapy for treating acute ischemic stroke may be increased in the following conditions and should be weighed against the anticipated benefits, which include:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Severe neurological deficit (e.g., NIHSS &amp;gt;22) at presentation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Major early infarct signs on CT scan (e.g., substantial edema, mass effect, or midline shift)&lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: aPTT = activated partial thromboplastin time; CT = computed tomography; INR = international normalized ratio; NIHSS = National Institutes of Health Stroke Scale; PT = prothrombin time&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul type=&quot;disc&quot;&gt;&#xD;&#xA;&lt;li&gt;The authors, editors, and publisher of this document neither represent nor guarantee that the practices described herein will, if followed, ensure safe and effective patient care. The authors, editors, and publisher further assume no liability or responsibility in connection with any information or recommendations contained in this document. These recommendations reflect the American Association of Neuroscience Nurses' judgment regarding the state of general knowledge and practice in their field as of the date of publication and are subject to change based on the availability of new scientific information.&lt;/li&gt;&#xD;&#xA;&#xD;&#xA;&lt;li&gt;Adherence to this guideline is voluntary. The ultimate determination about its application should be made by the practitioner who takes into consideration the unique circumstances presented by the individual patient. This reference is an essential resource for nurses who provide care to patients hospitalized with ischemic stroke. It is not intended to replace formal instruction but rather to augment the knowledge base of clinicians and provide a readily available reference tool.&lt;/li&gt;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Chart Documentation/Checklists/Forms" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /><FieldValue Value="Timeliness " /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Association of Neuroscience Nurses. Guide to the care of the hospitalized patient with ischemic stroke. 2nd ed. Glenview (IL): American Association of Neuroscience Nurses; 2008. 38 p.  [153 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2008 (reaffirmed 2012 Dec)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="American Association of Neuroscience Nurses - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American Association of Neuroscience Nurses&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;p&gt;Genentech&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Content Authors&lt;/em&gt;: Sue Pugh, MSN, RN, CNRN, CRRN, Subcommittee Chair; Claranne Mathiesen, MSN, RN, CNRN; Melissa Meighan, MS, RN, CNRN; Deborah Summers, MSN, RN, APCNS-BC, CNRN, CCRN, FAHA; Patricia Zrelak, PhD, CNAA-BC, CNRN&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The American Association of Neuroscience Nurses (AANN) requires that all planners, teachers, and authors involved in CNE make full disclosure indicating whether the individual and/or his/her family have any &lt;strong&gt;relevant financial relationships&lt;/strong&gt;, now or within the 12 months preceding this event, with a commercial interest (e.g., pharmaceutical companies, biomedical device manufacturers, and/or corporations) whose products or services are discussed in the continuing education activity content over which the individual has control. All presenters participating in the AANN sponsored programs must complete this form and return it as indicated. All information disclosed is printed in the program materials.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The authors state no potential conflicts of interest.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The American Association of Neuroscience Nurses reaffirmed the currency of this guideline in December 2012.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.aann.org/pdf/cpg/aannischemicstroke.pdf&quot; title=&quot;AANN Web site&quot;&gt;American Association of Neuroscience Nurses Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the American Association of Neuroscience Nurses, 4700 W. Lake Ave., Glenview, IL 60025.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A copy of the Barthel Index and a modified Rankin scale are available in the appendices of the &lt;a href=&quot;http://www.aann.org/pdf/cpg/aannischemicstroke.pdf&quot; title=&quot;AANN Web site&quot;&gt;original guideline document&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on September 9, 2009. The information was verified by the guideline developer on September 29, 2009. This summary was updated by ECRI Institute on July 27, 2010 following the FDA drug safety communication on Heparin. The currency of the guideline was reaffirmed by the developer in December 2012 and this summary was updated by ECRI Institute on October 22, 2013. This summary was updated by ECRI Institute on March 7, 2014 following the U.S. Food and Drug Administration advisory on Low Molecular Weight Heparins.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
